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OVERVIEW 
This thesis is submitted as part of the requirements for the degree of Doctorate in Clinical 
Psychology at The University of Birmingham. This thesis consists of two volumes which 
demonstrate clinical (Volume II) and research (Volume I) ability. 
Volume I 
The first volume consists of three chapters. The first is a systematic literature review 
examining what the evidence is for neurological and cognitive symptoms of coeliac disease 
and non-coeliac gluten sensitivity in adults. The second chapter presents a piece of research 
investigating whether illness perceptions are moderated and mediated through self-efficacy 
for the gluten free diet and coping for the outcomes of psychological wellbeing and quality of 
life. The final chapter is a brief public dissemination document that provides an overview of 
the research carried for this thesis. 
Volume II 
The second volume demonstrates clinical ability by presenting four clinical practice reports 
(CPR) and one CPR abstract for a report that was presented orally. CPR 1 describes 
assessment and formulation of 10-year-old boy referred to Child and Adolescent Mental 
Health Service (CAMHS) due to lifelong food neophobia and limited diet. CPR 2 is a service 
evaluation on how well a West Midlands CAMHS service follows the local anorexia nervosa 
pathway and how this pathway compares to the NICE guidelines for eating disorders (NICE, 
2004). The third CPR is a single case experimental design (SCED) aimed at reducing 
obsessive compulsive (OCD) checking behaviours in an 82-year-old woman who had been 
experiencing symptoms for around 60 years. CPR 4 is a case study of a 35-year-old male 
British military veteran with anxiety and post-traumatic stress disorder. The final CPR is the 
abstract of an oral presentation outlining a case study of a 29-year-old woman with borderline 
personality disorder using a dialectical behaviour therapy (DBT) framework. 
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ABSTRACT 
Introduction 
Coeliac disease (CD) and non-coeliac gluten sensitivity (NCGS) are generally identified by 
their gastro-intestinal symptoms. However, more recently there has been an increasing focus 
on the extra-intestinal symptoms of such conditions. Within the literature, these symptoms 
remain up to now somewhat under-explored and the data that does exist are reported across 
various disciplines. This review aims to combine data on the neurological and cognitive 
symptoms experienced by adults with untreated CD or NCGS from multiple disciplines and 
to assess the quality of this research using an established research quality framework.  
 
Method 
Six databases were searched (Medline, PsychARTICLES, PsychINFO, EMBASE, CINHAL 
and ProQuest), these results were combined with backwards and forwards reference searches 
and resulted in 114 articles. After application of the inclusion criteria, 21 studies were 
included for review; five qualitative and 16 quantitative. Studies including CD and NCGS, 
neurological e.g. slowed nerve function or altered sensation and cognitive symptoms e.g. 
memory difficulties or word-finding problems were included. These were assessed against 
Caldwell, Taylor and Henshaw’s (2005) quality framework. 
 
Results 
The literature gives the clearest picture of the neurological symptoms found in adults with 
CD and to a lesser extent NCGS, these studies are generally more robust. There is consensus 
as to what the symptoms are (slowed nerve conduction, neurological pain and altered 
sensation in hands and feet). The cognitive symptoms are less clear; there is no over-all 
agreement as to whether there are cognitive symptoms and certainly not which cognitive 
abilities are affected. This review tentatively suggests there is some evidence for short-term 
memory problems and fatigue, however, to accept these results with confidence further 
research focussing on this area would need to be conducted.  
 
Discussion 
The literature is complex and there are a number of issues that make it more difficult to be 
confident in the neurological and cognitive symptoms found in adults with untreated CD and 
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NCGS. Further high-quality research would help to clarify the picture. Studies varied in their 
designs and the methods used by different studies to assess cognitive symptoms were less 
consistent than those used to assess neurological symptoms. Neurological tests such as 
transcranial magnetic stimulation (TMS) were able to identify neurological symptoms before 
individuals were aware of them. This was not possible for cognitive symptoms, which mainly 
relied on self-report methods of identification. Response to a gluten free diet (GFD) varies 
depending on duration of gluten exposure, symptoms and GFD. The importance of early 
diagnosis and treatment in both CD and NCGS to prevent potentially permanent neurological 
damage is discussed.    
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INTRODUCTION 
Gluten is the collective name for the proteins found in wheat (Biesiekiersk, 2017) and other 
cereals such as barley, rye, oats and spelt (Kupper, 2005). There are a number of conditions 
related to gluten ingestion, these include, but are not limited to coeliac disease (CD) and non-
coeliac gluten sensitivity (NCGS) – which will be discussed in detail below - wheat allergy 
(Coeliac UK, 2017), dermatitis herpetiformis (DH) (Coeliac UK, 2017), and gluten ataxia 
(Baizabal-Carvallo & Jankovic, 2012) are all related to gluten ingestion. DH has no known 
cognitive or neurological symptoms associated with it (Coeliac UK, 2017; NICE, 2011). In 
contrast, gluten ataxia (GA), which is a relatively newly identified auto-immune mediated 
response to gluten (Hadjivassiliou et al., 2015), is wholly defined by neurological symptoms, 
such as poor balance and unusual sensations in the hands and feet (Hadjivassiliou et al., 
2003). Removal of gluten from the diet halts and even reverses symptoms in GA 
(Hadjivassiliou et al., 2008), which suggests gluten has a direct effect on symptoms. In terms 
of wheat allergy, ingestion of gluten leads to an allergic response, which includes the 
cognitive symptom of fatigue. These gluten-mediated conditions contain neurological and/or 
cognitive symptoms. If these symptoms are directly related to gluten, other gluten-mediated 
conditions may have similar extra-intestinal symptoms. 
In addition to wheat allergy, GA and DH, autoimmune conditions frequently co-occur with 
CD (Gujral et al., 2012; NICE, 2015) such as type 1 diabetes and autoimmune thyroid 
disease. Brands et al. (2005) and Dore et al. (2015) reported cognitive dysfunction in adults 
with type 1 diabetes in the areas of attention, psychomotor speed and visual perception even 
when control of diabetes is taken into account. Further to this, in 2005 Brands et al. 
concluded that processing speed and cognitive flexibility were mildly impaired in individuals 
with type 1 diabetes and McCrimmon et al. (2012) found memory and learning were affected 
by type 1 diabetes. Untreated hypothyroidism has an established link with cognitive 
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symptoms such as attention, concentration, language and memory difficulties (Cordes et al., 
2015; Davis & Tremont, 2007) and sub-clinical and/or untreated hypothyroidism can cause 
symptoms of dementia (Pasqualetti et al., 2015) in older adults. It is difficult to establish 
whether these neurological and cognitive effects are disease-specific or, instead, due to more 
general autoimmune processes, in which case similar symptoms in adults with CD could be 
expected.   
Inflammation is currently one of the leading theories for the cause of damage seen in a 
number of diseases including gastro-intestinal cancers (Eiro & Viscozo, 2012), Alzheimer’s 
disease (Tansey et al., 2017), diabetes (Weir & Bonner-Weir, 2017) and thyroid disease 
(Khan et al., 2015). The processes behind inflammation are complex, but in an autoimmune 
condition such as CD, gluten molecules trigger a cellular response that includes the 
production and release of pro-inflammation cytokines. These cells then attract others to 
combat the intruding molecules, causing inflammation. Diet has also been found to increase 
inflammation in healthy individuals that leads to cognitive decline (Ozawa et al., 2017) so an 
autoimmune condition is not required for cognitive abilities to be affected (Lionetti et al., 
2015). The most inflammatory dietary pattern is one high in red and processed meats, 
legumes and some vegetables, but low in whole grains. Individuals who cannot eat gluten 
will not be eating whole grains and may be more susceptible to the role of inflammation. 
Inflammation is likely to be strongest in the areas where gluten is most highly concentrated, 
namely the gut and brain. 
 
Coeliac Disease 
CD is an autoimmune condition triggered by the ingestion of gluten in genetically susceptible 
individuals. It was previously thought to be a disease of childhood (Hallert & Astrom, 1983), 
however, individuals are most frequently diagnosed between 40 – 60 years of age (Coeliac 
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UK, 2017). Gluten elicits an immune response and damage occurs to the villi of the small 
intestine. These hair-like structures (villi) absorb nutrients from food and villous atrophy is 
the term used to describe the flattening of the villi as a result of this auto-immune assault. 
Flattened villi significantly reduce the surface area of the small intestine, which results in a 
significant reduction in absorption, and nutritional deficiencies (Kupfer, 2009).  
Prevalence of CD correlates with the amount of gluten containing foods typically consumed 
in the national diet and global rates vary (Hischenhuber et al., 2005; Koning, 2012). The UK 
reports around 1% of the population have CD (NICE, 2015), although CD is thought to be 
underdiagnosed (NICE QS134, 2016; Coeliac UK, 2017).  
Stepkiak & Koning (2003) outline three factors that are required for the onset of CD, namely 
(1) a genetic predisposition, (2) a gluten containing diet and (3) a trigger (also Sollid & Jabri, 
2013). Gastrointestinal infections are commonly reported as occurring before the onset of CD 
(Evans et al., 2012). Although there are some conflicting findings (Troncone et al., 2007) the 
most widely accepted explanation for the development of CD is that an appropriate immune 
response to an invading pathogen continues to respond to gluten after the initial infection is 
removed (Troncone et al., 2007). 
 
Symptoms 
Symptoms described by individuals with CD most commonly include gastrointestinal 
problems such as diarrhoea or constipation, bloating, pain and discomfort (Coeliac UK, 
2017). There are also extra-intestinal symptoms, such as fatigue, weight loss and headaches 
(Bushara, 2005; NICE, 2015).  
More recently, research literature is starting to emerge on the topic of CD “brain fog” 
(Yelland, 2017; Campagna et al., 2017), which up to this point has been a term frequently 
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used by the “CD community” - in forums and support groups - to describe what may be 
transient, mild, cognitive impairment. Anecdotally, people with CD have reported cognitive 
symptoms as the first indication of gluten exposure. However, there has been little empirical 
investigation of “brain fog” in CD to date, but Yelland (2017) identified memory, attention, 
executive function and processing speed as reported symptoms of “brain fog”. Cognitive 
impairment or “brain fog” is not exclusive to CD and has been examined in more detail in 
other conditions such as chronic fatigue syndrome (CFS: Jorgenson, 2008; Ocon, 2013) and 
postural tachycardia syndrome (Ross et al., 2013). Within CFS “brain fog” has been 
conceptualised as involving cognitive symptoms of poor attention, concentration and 
difficulty focussing on tasks (Ocon, 2013), as well as neurological symptoms of slowed 
reaction times (Cockshell & Mathias, 2010). Ross et al. (2013) reported similar findings of 
memory problems, attention and concentration difficulties and finding it hard to focus on 
tasks in their investigation of participants with postural tachycardia syndrome and “brain 
fog”. 
 
Diagnosis and Management 
Diagnosis is made via blood test and confirmatory biopsy if CD-specific antibodies are found 
or if symptoms persist in the absence of antibodies (NICE NG20, 2015; NICE QS134, 2016). 
There is no cure for CD and treatment involves removing the immune response-triggering 
molecule from the diet by following a lifelong gluten free diet (GFD) (NICE, 2015). This diet 
allows the villi to recover and within 12 months of a GFD commencing 27-66% of 
individuals’ intestines show no damage (rate of recovery is related to severity of disease; 
Corbett et al., 2012; Galli et al., 2014), and levels of CD-specific antibodies have reduced to a 
normal range in 43% of individuals (Corbett et al., 2012). Patients with CD typically report 
improvement in gastro-intestinal symptoms immediately after starting a GFD, whereas for 
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some the improvement is more gradual (Coeliac UK). Gastro-intestinal symptoms may 
reduce rapidly after the start of a GFD, but extra-intestinal symptoms can take longer to 
resolve (www.celiac.com).  
Research using adult samples has found long-term, undiagnosed CD can result in several 
nutritional deficiencies and conditions related to malabsorption, which need to be treated 
alongside a GFD (American College of Gastroenterology, 2013; Urban-Kowalczyk et al. 
2014). The most common of these conditions tends to be iron deficiency with or without 
anaemia (Carroccio et al., 1998), vitamin B12 deficiency, folic acid deficiency (Hu et al., 
2006) and calcium deficiency.  
 
Non-Coeliac Gluten Sensitivity 
NCGS has previously been known as gluten sensitivity (Sapone et al., 2010). Despite the 
considerable overlap of symptoms of NCGS and CD reported below, the conditions are 
separate; the defining characteristic of NCGS is the presence of healthy villi cells in the small 
intestine (Lundin & Aleadini, 2012). The history of NCGS in the literature suggests that prior 
to the 1970s there was some investigation into gluten sensitivity, however the condition 
became lost and individuals with NCGS were either diagnosed as having CD or not 
diagnosed, but treated with a GFD (Catassi, 2015). NCGS is believed to affect more 
individuals than CD (Volta et al., 2014), however, due to the lack of a consistent definition 
the true rates are hard to establish. Sapone et al. (2012) reported an incidence rate of 6% 
whereas the Continuous National Health and Nutrition Examination Survey (CNHANES) a 
year later reported 0.55% of the population of the United States suffered from NCGS (Di 
Giacomo et al., 2013).  
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Symptoms 
Due to the relative neglect of this condition there remains poor universally recognised 
symptomatology of NCGS (Di Sabatino et al., 2015) and cases are often self-reported 
(Rostami & Hogg-Kollars, 2012). Commonly reported symptoms of NCGS are similar to 
those of CD (Sapone et al, 2012; Sapone et al., 2015; Volta et al., 2012). As with CD, extra-
intestinal complaints are also recognised (Yelland, 2017), the most frequently reported of 
which are fatigue and headaches (Volta et al., 2012). Numbness or altered perception in the 
extremities, such as pins and needles sensations, are also reported (Catassi et al., 2015). 
 
Diagnosis and Management 
For NCGS, no serological markers are known, however, this may change as the condition 
benefits from more attention, discussion and publication (Catassi et al., 2012; Volta et al., 
2015). Within the literature diagnostic criteria are being developed for clinical use (Catassi et 
al., 2015; Catassi et al., 2013).  
As with CD, the only effective treatment for NCGS is lifelong adherence to a GFD (Holmes, 
2013). For some, gastro-intestinal symptoms remain even on a GFD, possibly due to other 
food intolerances (Catassi, 2015).  
 
Aims 
As discussed above, some of the conditions that occur as a result of gluten ingestion have 
neurological symptoms associated with them; in fact, GA is wholly defined by neurological 
symptoms. Other autoimmune conditions that frequently occur with CD (e.g., Type 1 
diabetes) have been shown to be associated with neurological and cognitive symptoms. The 
defining characteristic of CD is that it is a gluten-mediated autoimmune response and, as 
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such, it is likely that there are neurological and cognitive symptoms associated with the 
condition, as have been found in other autoimmune conditions and as have been reported by 
patients with CD. Published literature on CD has focussed more on the medical and 
biological symptoms of the condition and response(s) to a GFD, while extra-intestinal 
symptoms (including cognitive and neurological symptoms) have been relatively neglected.   
In contrast NCGS has suffered from under-investigation across all areas - little is known 
about the extra-intestinal symptoms related to this condition. It was decided therefore to 
include NCGS in this review partly to add to what is known about the condition. However, 
most significantly, including NCGS (with its symptomology that matches CD to such a 
degree, without it being an autoimmune condition) would help in identifying whether the 
neurological and cognitive symptoms seen in CD are related to gluten itself rather than an 
autoimmune process.  
A complication of the extant literature is that evidence for cognitive and neurological 
symptoms is spread across a number of discipline areas; no review exists that has collated 
data to explore the evidence and quality of evidence for cognitive and neurological symptoms 
in CD and NCGS.    
This review aims to combine data on the neurological and cognitive symptoms of adults with 
untreated CD or NCGS from multiple disciplines by: 
1. Reviewing the literature on the cognitive and neurological symptoms of adults with 
untreated CD and NCGS, and 
 
2. Assessing the quality of this research using an established research quality framework 
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METHODOLOGY 
Search strategy 
Six databases were originally searched in November 2016: Medline (1946-2016), 
PsychARTICLES, PsychINFO (1967-2016), EMBASE (1947-2016), CINHAL and 
ProQuest. The same search process was repeated in October 2017 to identify any new, 
additional, articles relevant for inclusion. Search terms were defined for the purpose of this 
review taking the key terms from the title (Figure 1). 
Childhood CD can be related to complex conditions such as epilepsy (Mavroudi et al., 2005) 
and emotional disturbances (Da Silva Kotze et al., 2000) and identifying the symptoms 
related to CD or NCGS, but excluding those relating to other conditions, would be beyond 
the scope of this review. Similarly, in the elderly there is some cross-over between symptoms 
of dementia and the cognitive and neurological symptoms of CD and NCGS. Given the 
complexities of these two age-related samples in allowing a differentiation of CD 
neurological and cognitive symptoms from other associated conditions, childhood CD and 
CD in the elderly were excluded from the present review. As the majority of diagnoses of CD 
occur in adulthood (Coeliac UK) literature was restricted to studies relating to adult 
participants (18-65 years). 
GA was not included as a search term as it is recognised as a separate autoimmune condition 
that can occur with or without CD. Research investigating GA has been included in the 
review as long as participants had CD or NCGS and met the requirements of the other 
inclusion criteria. 
 
Search terms (Figure 1) were combined, as follows: neuro* OR cognitive* AND adult* or 
working age AND celiac or coeliac or gluten free diet AND gluten intol* or gluten sensi* 
12 
 
 
Figure 1: Search terms derived from title of review 
 
The terms ‘cognitive’ and ‘neurological’ were searched separately before results were 
combined to ensure all articles were captured by the search.  
Combining the above terms resulted in 156 articles. Four further articles were identified from 
backwards and forwards reference searches of the final articles. Duplicate articles (46) were 
removed and the remaining 114 abstracts reviewed to establish eligibility in relation to the 
inclusion criteria (Table 1). To identify cognitive and neurological symptoms the following 
definitions were used: 
Cognitive - Relating to mental processes e.g. perception, memory, judgment, knowing, 
learning and reasoning - based on the definition provided by Collins English Dictionary 
(2016). 
Neurological - Of or relating to the nervous system e.g. structural, biochemical or electrical 
abnormalities in the brain, spinal cord or other nerves - based on the definition provided by 
Collins English Dictionary (2016).  
Following the application of the inclusion criteria, 88 articles were removed (Appendix A) 
leaving 26 for full article review; five articles were not available (Appendix B). A total of 21 
articles met inclusion and were reviewed (Figure 2). 
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Table 1: Inclusion criteria applied to retrieved abstracts 
Inclusion criteria 
1. Cognitive and/or neurological symptoms1 measured and 
reported 
2. Studies including participants with formally diagnosed 
CD 
3. Studies including participants with self-reported NCGS2 
4. Participants not on a GFD when neurological and 
cognitive symptoms were assessed or reported 
5. Studies reporting on original data 
6. Participants primarily between 18-65 years of age3 
7. Quantitative and/or qualitative study 
8. Case study4 
9. Full text English language available 
 
In total, five articles were qualitative and the remaining 16 were quantitative. Eighteen used 
participants with CD, two with NCGS, and one with both. Twelve studies measured and 
reported neurological symptoms, three only cognitive symptoms, and six included both 
neurological and cognitive symptoms. 
 
 
 
 
 
                                                 
1 Research must include measurement and reporting of cognitive and/or neurological symptoms  
2 As no standardised diagnostic criteria is currently in use for NCGS, studies including participants who self-
reported NCGS were included 
3 If data from participants outside of this age range could be differentiated in the results this was done by the 
author and not reported. If this was not possible the study was included if mean age was between 18-65 years 
and all other inclusion criteria were met 
4 Case studies can be the first type of published research and in some areas, for example, in neuropsychology 
this is customary. Case studies were included so as not to lose valuable data on emerging areas across 
disciplines 
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Figure 2: Flowchart of article selection 
 
Search Results 
For each included study, a data extraction form was used to capture the details of the papers 
relevant to this review, and an overall summary of each of the papers is shown in Table 2, 
studies are presented alphabetically.  
Records identified through  
database searching 
Medline n=85 
PsychARTICLES, PsychINFO 
and EMBASE n=67  
CINHAL n=3  
ProQuest n=1 
(n =156) 
Records identified through  
other sources 
Forwards and backwards 
reference searches n =4 
Records after duplicates removed 
(n = 114) 
Records screened 
(n = 114) 
Qualitative and quantitative 
studies included in synthesis 
(n = 21) 
Records excluded 
(n = 88) 
Full text not available 
(n = 5) 
Full text articles assessed for 
eligibility 
(n = 26) 
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Table 2: Summary of studies included in review 
Study Type/ 
Aims 
Sample 
Intervention or 
Investigation 
Neurological and Cognitive 
Symptoms 
Key Findings Limitations 
1. Alaedini, Green, Sander, Hays, Gamboa, Fasano, Sonnenberg, Lewis & Latov (2002) 
Investigation of anti-
ganglioside 
antibodies as an 
explanation of 
neuropathy in CD 
patients. 
- 27 participants with CD 
(42-53 years) 
- 6 patients with Motor 
Neuron Disease 
- 20 patients with Multiple 
Sclerosis 
- 40 healthy controls 
(negative control) 
- Patients with Guillian-
Barre syndrome (positive 
controls) 
 
- Individuals who had 
increased anti-
ganglioside 
antibodies were given 
a detailed 
neurological 
examination 
 
- Numbness and pins and 
needles in hands and feet 
- Pain 
 
 
- The body’s 
autoimmune response to 
gluten has a role to play 
in the neurological 
symptoms seen in CD 
- Only 6 participants 
were examined 
neurologically 
- It is not known how 
many individuals 
without CD would also 
show these symptoms 
- Study cannot 
establish cause and 
effect 
2. Cervio, Volta, Verri, Boschi, Pastoris, Granito, Barbara, Parisi, Felicani, Tonini & De Giorgio (2007) 
Investigation into the 
mechanism 
underlying 
neurological 
impairment in CD. 
 
Aims to investigate 
whether the sera of 
patients with CD 
cause apoptosis of 
neuronal cells. 
- 9 participants (3 male) with 
CD, neurological symptoms 
and anti-neuronal antibodies 
(21-61years) 
- 6 participants (1 male) with 
CD, no neurological 
symptoms and without anti-
neuronal antibodies 
- 4 participants (2 male) 
without CD, but with 
neurological disorders 
- 10 healthy controls 
- Animal subjects 
N/A 
- Cerebellar ataxia (unsteady 
gait and poor muscle 
coordination) 
- Poor memory 
- Poor attention 
 
Other neurological conditions 
present: 
- Multiple sclerosis 
- Epilepsy 
- Moyamoya disease 
 
- The study concluded 
that specific damage 
occurs to neuronal cells 
via an immune-mediated 
pathway in adults who 
show anti-neuronal 
antibodies 
- The presence of anti-
neuronal antibodies 
alone are not enough to 
cause neurological 
symptoms 
- Results are too 
general to be specific 
to CD 
- Small sample 
- Sample “selected” 
(page 196) and 
selection not defined 
 
3. Cicarelli, Della Rocca, Amboni, Ciacci, Mazzacca, Filla & Barone (2003) 
Comparison between 
2 groups with CD 
(classical and 
subclinical) and age 
matched controls 
 
- 127 participants with 
classic CD (16-76 years) 
- 49 participants with 
subclinical CD (19-67 years) 
- 52 healthy controls 
N/A 
- Migraine 
- Tension headache 
- Mixed type headache 
- Pins and needles 
- Muscle weakness 
- Reduction of vibratory 
response 
- No difference between 
classic or subclinical CD 
- No signs of nutritional 
deficiencies 
- Correlation between 
length of untreated 
- Compared separate 
groups 
- Correlations can’t 
establish cause and 
effect 
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To identify the 
occurrence and 
frequency of subtle 
neurological 
symptoms in adults 
with CD 
- Poor reflexes 
 
Other neurological conditions 
present: 
- Epilepsy 
disease and number of 
neurological symptoms 
- No ataxia found 
4. Collin, Kaukinen, Mattila & Joukamaa (2009) 
Between subjects 
study 
 
Aiming to compare 
the levels of 
alexithymia in adults 
with CD with non-
CD controls 
- 20 participants (5 male) 
with CD (16-72 years) 
- Data for controls was taken 
from previous population 
studies 
 
- GFD 
- The Crown and 
Crisp Experiential 
Inventory (CCEI) 
- The Toronto 
Alexithymia Scale 
(TAS-20) 
- No difference in alexithymia 
 
Other neurological conditions 
present: 
- Epilepsy 
- Coeliac patients did not 
show more 
psychoneurotic 
symptoms than the 
controls 
- There was an 
insignificant trend 
towards improvement in 
scores 
- Only 2 participants 
showed alexithymia 
- Reliance on 
subjective accuracy is a 
limitation of all self-
report measures 
- Small sample size 
- Control data from 
previous studies used, 
not matched to this 
study and participants 
5. Di Sabatino, Volta, Salvatore, Biancheri, Caio, De Giorgio, Di Stefano & Corazza (2015) 
A randomized, 
double-blind, 
placebo-controlled, 
cross-over trial. 
 
To investigate the 
intestinal and extra-
intestinal effects of 
low levels of gluten 
ingestion on adults 
who have self-
diagnosed NCGS 
- 59 participants with self-
diagnosed NCGS 
Week 1 GFD 
Week 2 4.375g of 
gluten or 4.375g of 
rice starch as a 
placebo 
Week 3 GFD 
Week 4 alternate arm 
of study 
Week 5 GFD 
Self-reported 
questionnaires of 
symptoms 
- Headache 
- Fatigue 
- Malaise 
- Foggy mind 
- Joint pain 
- Other pain 
- Pins and needles in hands 
and feet 
 
(most common at the top) 
- Gluten ingestion led to 
significantly more 
symptom severity than 
placebo 
-3 patients identified as 
having NCGS 
-Depression was among 
the top 5 symptoms 
reported 
- Nocebo effects 
- Relatively short wash 
out period and 
ingestion period for 
gluten 
- Only 3 participants 
did have NCGS 
- Presence or absence 
of CD not explained 
6. Gao, Dhiren Varma, Patel, Lee & Chen (2015) 
Case study 
- A 58-year-old male with 
permanent, but partial sight 
loss and CD 
N/A 
- Partial sight loss and 20 
years CD 
- Bilateral occipital 
calcifications (deposits of 
calcium in the brain, in this 
- Male with 40 years 
sight loss and 20 years 
CD 
- CD now well controlled 
 
- Case study 
- Unable to determine 
cause 
- Unable to generalise 
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case on the areas that control 
the eyes) 
7. Hadjivassiliou, Davies-Jones, Sanders & Grunewald (2003) 
A longitudinal 
between and within 
subjects’ design 
 
To (1) establish any 
therapeutic effect of 
GFD on the treatment 
of gluten ataxia (GA) 
and (2) establish 
whether the nervous 
system can be the 
sole target organ of 
an immune mediated 
disease triggered by 
gluten 
- 26 participants with GA 
who adhered to a GFD (8 
had CD) (28-84 years) 
- 14 participants with GA 
who did not follow the GFD 
(1 had CD) (38-82 years) 
- GFD 
- Ataxia 
- Slowed fine motor control 
 
 
- GFD group showed 
reduction in GA 
symptoms 
- Inflammation plays a 
role in GA 
- Those with the shortest 
history of GA returned to 
normal functioning  
- No randomisation 
- Bias due to one 
investigator doing all 
testing 
- Identical “clinical 
picture” (p 1222) for 
those with and without 
CD, however 
improvement in 
outcomes only 
“apparent” (p 1222) 
after removing 
participants with CD 
8. Hadjivassiliou, Kander, Chattopadhyay, Davies-Jones, Jarratt, Sanders, Sharrack & Grunewald (2006)  
With and between 
subjects repeated 
measures cohort 
study 
 
To assess the effect 
of a GFD on gluten 
neuropathy  
- 25 participants with gluten 
neuropathy who followed a 
GFD (7 had CD) (63-65 
years) 
- 10 participants with gluten 
neuropathy who did not 
follow a GFD (control)  
- GFD 
 
- Tingling in hands and feet 
- Numbness 
- Pain 
- Unusual sensation e.g. sharp 
stabbing pains 
- Slowed nerve response to 
stimulus 
- Reduced nerve response to 
stimulus 
- 64% of GFD group 
reported symptoms 
improved compared to 
only 12% in the non-
GFD group 
- Symptoms worsened 
with time and exposure 
to gluten as did outcomes 
for recovery 
- Partial adherence to 
GFD partially improves 
neurological symptoms 
- Follow-up over a 
brief period, may not 
allow all improvements 
to be identified 
- Patients without CD 
included 
- Presence of 
antibodies may not be a 
reliable measure of 
GFD adherence 
- No randomisation 
9. Hadjivassiliou, Rao, Grunewald, Aeschlimann, Sarrigiannis, Hoggard, Aeschlimann, Mooney & Sanders (2015) 
Between subject 
design 
 
Aim to compare and 
identify differences 
in neurological 
- Group 1 (with CD) 228 
participants 
- Group 2 (NCGS) 334 
participants  
- Retrospective 
analysis of case notes 
Group 1 
- Ataxia (severe) 
- Weakness, numbness and 
pain in hands, feet, arms and 
legs 
- Encephalopathy more 
common in Group 1 and 
neuropathy more 
common in Group 2 
- Neuropathy more 
severe in Group 1 
- Retrospective review 
of notes – not all 
tests/assessments 
available for all 
participants 
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dysfunction in 
individuals with CD 
and NCGS 
- Encephalopathy (changes to 
the brain) 
Group 2 
- Weakness, numbness and 
pain in hands, feet, arms and 
legs 
- Ataxia (mild) 
- Encephalopathy (changes to 
the brain) 
- No difference in ataxia 
- Both groups equally 
benefitted from GFD 
10. Hallert & Astrom (1983) 
Between subjects 
design 
 
Aims to identify 
whether intellectual 
impairment is a 
feature of untreated 
CD 
- 19 newly diagnosed adults 
with CD (37-59 years) 
- The synonyms 
reasoning block test 
- Thurnstone’s 
memory test 
- Reaction time 
(simple and 3-choice 
stimulation) 
- Figure identification 
- Figure rotation 
- Finger dexterity 
- Benton’s visual 
retention test 
- No cognitive impairment 
- No signs of intellectual 
impairment in adults 
with newly diagnosed 
CD 
- Irrespective of whether 
CD was developed in 
adulthood or childhood 
- Unclear whether any 
participants were on a 
GFD at any point in the 
study 
- Small sample size 
 
 
11. Hu, Murray, Greenaway, Parisi & Josephs (2006) 
Retrospective case 
series from existing 
clinical notes 
 
Describes profiles of 
patients who reported 
cognitive symptoms 
2 years prior to CD 
diagnosis 
- 13 participants with CD 
who had reported 
neurological symptoms 
within 2 years of diagnosis 
- Neurological and 
cognitive assessment 
data, EEG and MRI 
scans where data 
were available 
- Amnesia 
- Acalculia 
- Confusion 
- Disorientation 
- Dysgraphia 
 
- 10 patients deteriorated 
cognitively 
Other common 
symptoms: 
- Personality change 
- 2 improved following 
GFD 
- No pattern to EEG 
findings 
- CJD initially diagnosed 
in 1/3 of patients 
- Consistent data for 
analysis between 
individuals not present 
- Not able to establish 
cause and effect 
- Very small sample 
sizes 
- Not able to generalise 
results 
12. Ihara, Makino, Sawada, Mezaki, Mizutani, Nakase, Matsui, Tomimoto & Shimohama (2005) 
Case series and a 
case report 
 
- 14 participants with 
idiopathic cerebellar ataxia 
N/A 
- Cerebellar atrophy 
- Slowed cerebral blood flow 
- Mild cognitive impairment 
- MRI showed cerebellar 
atrophy in 10 participants 
- Small sample size 
- Unable to identify 
cause and effect 
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To investigate 
whether gluten 
sensitivity (NCGS) is 
present in adults who 
are experiencing 
sporadic cerebellar 
ataxia 
with extra-cerebellar 
symptoms (44-84 years) 
- 9 individuals with 
Parkinson’s disease 
- 18 participants with ALS 
- 47 healthy controls 
and slowed blood flow in 
all but one participant 
- In the experimental 
group, participants were 
more likely to be AGA 
IgG or IgA positive 
- Mild cognitive 
impairment was more 
prevalent in the AGA 
positive group 
- Ataxic patients are 
more likely to have 
NCGS 
- Unclear whether 
participants had CD or 
what would now be 
termed NCGS 
13. Lichtwark, Newnham, Robinson, Shepherd, Hosking, Gibson & Yelland (2014) 
A longitudinal study 
to investigate 
mucosal healing and 
cognitive function in 
adults with CD 
- 11 participants (8 female) 
with CD (22-39 years) 
- GFD 
Improved scores following 
GFD found in: 
- Verbal fluency 
- Attention 
- Motoric function 
Alongside cognitive 
improvement GFD 
correlated with: 
- Improved mucosal 
healing 
- Reduction of CD 
antibodies 
- Small sample size 
- Can’t be generalised 
 
 
14. Millington, James-Galton, Barbur, Plant & Bridge (2015) 
Case study 
- A 54-year-old woman with 
CD. She has visual 
disturbance that is stable and 
permanent 
- 12 control subjects who 
have visual disturbance 
resulting from stroke 
N/A 
- Extensive damage to the 
occipital lobe 
- Evidence of calcification 
- Visual problems 
- Treatment for CD did 
not improve visual 
problems, but may have 
stabilised it 
- Importance of early 
diagnosis and treatment 
to prevent visual damage 
- Case study 
- Can’t be generalised 
- Complex history, 
causal link between CD 
and visual problems 
not clear 
- Implications of study 
not clear 
15. Pennisi, Lanza, Giuffrida, Vinciguerra, Puglisi, Cantone, Pennisi, D’Agate, Naso, Aprile, Malaguarnera, Ferri & Bella (2014) 
Between subjects 
design 
 
Aim to identify if 
there is a pattern of 
excitability of the 
- 20 CD patients (4 male) 
not on a GFD (24-45 years) 
- 20 age-matched controls (8 
male) 
- Mini Mental State 
Examination 
(MMSE) 
- Structured Clinical 
Interview for DSM-
IV Axis I Disorders  
(SCID-I) 
- Tiredness/Fatigue 
- Normal cognitive function 
- Different 
electrophysiological changes 
in the motor cortex of 
participants with CD 
 
- All participants had 
normal MMSE 
CD participants scored 
more highly on 
depression scale 
- MMSE may not be 
sensitive enough to 
capture mild cognitive 
change 
- TMS does not 
provide cause for 
change 
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motor cortex found in 
CD individuals 
- Hamilton 
Depression Rating 
Scale 
- EEG 
- CT scan 
- Single and paired 
TMS (transcranial 
magnetic stimulation) 
 
Other autoimmune conditions: 
- Hypothyroidism 
- Asthma 
- Vitiligo 
- 5 CD participants had 
dysthymic disorder 
(SCID-I) 
- Small sample 
- Can’t be generalised 
16. Poloni, Vender, Bolla, Bortolaso, Constantini & Callegari (2009) 
Case study 
- A 38-year-old Italian male 
with a neurological and 
psychiatric presentation of 
CD initially without signs of 
malabsorption 
N/A 
- Mild, non-specific, non-focal 
abnormalities on EEG 
- Muscle rigidity 
- Psychomotor slowing 
- Progressive frontal cognitive 
deficit (affective and 
behavioural lability) 
- Loss of language 
- Patient showed 
improvement of all 
symptoms following 
diagnosis of CD and 
commencing a GFD 
- Single case 
- Can’t be generalised 
- Can’t establish cause 
and effect 
17. Rigamonti, Magi, Venturini, Morandi, Ciano & Lauria (2007) 
Two case reports 
 
- A 26-year-old woman with 
sporadic gastro-discomfort 
after eating carbohydrate 
since childhood 
 
- - - - - - - - - - - - - - - - - - - -  
 
- A 62-year-old woman with 
no gastrointestinal 
complaints 
N/A 
- Lower and upper limb 
weakness 
- Lower reflexes absent 
- Poor nerve conduction in 
extremities 
 
- - - - - - - - - - - - - - - - - - - - -  
 
- Progressive hand and leg 
weakness 
- Slowing of nerve conduction 
- Both patients showed 
improvement of muscle 
strength and other 
neurological symptoms 
following 
commencement of a 
GFD 
- A direct pathogenic 
effect of gluten 
suggested 
- Single cases 
described 
- Can’t be generalised 
- Can’t establish cause 
and effect 
18. Somay, Cevik, Halac, Arbut & Erenoglu (2004) 
Case report 
- 32-year-old woman with 
CD 
N/A 
 
 
- Ataxia 
- Pain 
- Leg weakness 
- Tingling in legs 
- Pinprick and temperature 
sensation reduced in hands 
and feet 
- Ataxia and neuropathy 
symptoms improved at 2-
month follow-up 
- Oral pigmentation 
remained 
- Unable to establish 
cause due to multiple 
interventions 
- Single case described 
- Can’t be generalised 
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19. Souayah, Chin, Brannagan, Latov, Green, Kokoszka & Sander (2008) 
Multiple case series 
 
Investigating the 
effect of intravenous 
immunoglobulin 
(IVIG) on ataxia and 
neuropathic pain in 
adults with CD 
- (1) A 32-year-old woman 
with CD 
- (2) A 41-year-old woman 
with CD 
- (3) A 42-year-old woman 
with CD 
All treated with 
initial high dose of 
IVIG followed by a 
maintenance dose 
 
- Dysarthria (inability to 
produce clear speech) 
- Ataxia 
- Progressive numbness 
- Tingling or stabbing pains in 
fingers, face and legs 
- Neuropathic pain 
- Impaired fine motor control 
- Reduced pinprick and light 
touch sensation in legs 
- Poor balance 
- Absent vibratory response in 
feet 
- Within 1 month ataxia 
and neuropathy 
improved 
 
- Single cases 
described 
- Can’t be generalised 
- No statistical 
information reported 
- Not noted how 
adherence to GFD was 
evaluated 
 
20. Stipic, Perkovic, Crnek-Kunstelj, Relja, Stipic-Markovic & Skreb (2002) 
Case study 
- A 47-year-old woman with 
CD 
N/A 
- Paraparesis (partial loss of 
movement in all limbs) 
- Urine incontinence 
- Fatigue 
- Headache 
- Pain in legs and back 
- At 3 months clinical 
and haematological 
symptoms improved 
- Single case studied 
- Complexity of 
treatment makes it 
impossible to identify 
what caused the 
improvements 
- IQ at baseline, no 
follow-up or pre-
morbid measure taken 
21. Tursi, Giorgetti, Iani, Arciprete, Brandimarte, Capria & Fontana (2005) 
Between subjects 
design 
 
Aim to 
neurologically 
evaluate adults with 
untreated CD 
 
- 32 (7 male) participants 
newly diagnosed with CD 
and not on a GFD 
 
 
- Neurological 
investigation 
- Electroneuromyo-
graphy (ENMG) 
- CT scanning 
- GFD 
- Tingling or numbness in 
hands and feet 
- Muscle weakness 
- Recurrent feinting 
- Motor slowing 
- Touch insensitivity 
 
- 12 patients did not 
improve during GFD 
- Bowel atrophy 
improved  
- CD antibodies still 
present in 2 participants 
- No cerebral alterations 
- No control group 
- Small sample 
- Self-report measure 
of adherence to GFD 
may not be reliable 
- Not all the 
participants had 
neurological symptoms 
- Unable to establish 
cause and effect 
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Description of Studies 
Eighteen of the 21 studies (86%) included participants with CD (studies 1-4, 6-8, 10, 11 & 
13-21); of the remaining three studies, 2 (67%) focused on NCGS (5 & 12) and one included 
participant groups with CD and NCGS (9).  
Publication dates for the studies identified above ranged from 1976 – 2017. Articles were 
included from across the globe with the majority being published in Italy (2, 3, 5, 16, 17 & 
21), followed by the UK (7-9 & 14), the USA (1, 11 & 19), and Australia (6 & 13). One 
article each from Canada (15), Croatia (20), Finland (4), Japan (12), Turkey (18) and Sweden 
(10) made up the remaining studies. 
There was variation in the methodological designs used across studies:  nine case studies or 
multiple case series (6, 11, 12, 14 & 16-20); seven used a within-subjects design with follow-
up over 12 months (4, 10, 13 & 21) or data collected at one time-point only (1, 2 & 15); four 
used between groups methods with controls (3, 7 & 8) or different groups based on CD or 
NCGS (9); and one study utilised a randomised, double-blind, placebo-controlled cross over 
trial (5).  
The number of participants in each study ranged from one (6, 16 & 20) to 562 (9), with 81% 
of the 21 articles (n=17) having between 1 – 35 participants. Only nine studies (43%) 
included control groups, three exclusively used healthy controls who were fit and well (2, 3 
& 14), while the majority included controls with other conditions (4, 6 & 11) such as motor 
neurone disease (1), other neurological conditions (11) or used a control group with CD that 
refused a GFD while the treatment group complied (7). 
Demographic information on age of participants was not provided by two studies (9 & 11). 
Where ages were published, they ranged from 26– 84 years. Studies reported different 
demographics in terms of the duration of difficulties or symptoms, with some reporting age 
of diagnosis and age of symptoms onset (9 & 11) and others reporting the duration of relevant 
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symptoms (6 & 11). Due to the variation across the studies it was not always possible to 
record the duration of CD, NCGS, cognitive or neurological symptoms; however, where 
these data were provided, duration of untreated symptoms ranged between < 1 – 20 years. 
When reported, methods of diagnosis for CD did not vary. Some studies accepted formal 
diagnosis from participant case notes (13), or because participants were receiving care from 
the relevant service (8) and a diagnosis had already been formally established. However, 
when diagnosis of CD had not already been acquired, all studies required confirmation by 
biopsy (6, 7, 8 & 14). Response to a GFD was viewed as confirmatory of CD or NCGS, but 
not diagnostic; in one study, inclusion was withdrawn from participants with CD who did not 
respond to a GFD (2). 
 
Quality Assessment Framework 
Due to the variation in methodology across the included studies, it was important to assess 
the quality of each using a published quality assessment framework. Even well-designed 
studies can include bias and applying a framework to studies allows the level of bias to be 
measured and the results from less biased studies to be given greater weight in the reporting 
of the results. The framework used here is that from Caldwell, Taylor and Henshaw (2005), 
which was developed specifically for use in health research and provides the framework for 
“a detailed critique of a piece of published research” (Caldwell et al., 2005: pg 45) to inform 
practice. This quality framework allows qualitative and quantitative studies to be considered 
side by side using matched criteria (Figure 3). It was developed after the authors evaluated 
several quantitative, qualitative and mixed (Caldwell et al, 2005) frameworks and assesses 
both internal and external validity. 
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Figure 3: Questions included in Caldwell, Taylor and Henshaw’s (2005) quality assessment 
framework 
 
Caldwell, Taylor and Henshaw’s (2005) quality framework provided the questions to enable 
analysis of studies, but did not provide guidance of how to score studies against these 
questions. The Cochrane Handbook (Higgins & Green, 2011) advises the use of 3 levels to 
 1. Does the title reflect the content? 
2. Are the authors credible? 
3. Does the abstract summarise the key 
components? 
4. Is the rationale for the research clear? 
5. Is the literature review comprehensive and 
up to date? 
6. Is the aim of the research clearly stated? 
7. Are all ethical issues identified and 
addressed? 
8. Is the methodology identified and 
justified? 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
16. Are the results presented clearly and 
appropriately? 
17. Are the results transferable and 
Quantitative 
9a. Is the design identified and the rationale 
for it evident? 
10. Is the experimental hypothesis stated? 
11a. Are the key variables clearly defined? 
12a. Is the population identified? 
13a. Is the sample described and reflective of 
the population? 
14a. Is data collection valid and reliable? 
15a. Is data analysis valid and reliable? 
  
Qualitative 
9b. Are the philosophical background and 
design identified and the rationale for it 
evident? 
11b. Are the major concepts identified? 
12b. Is the context of the study outlined? 
13b. Is the selection of participants 
described and the sampling method 
identified? 
14b. Is data collection auditable? 
15b. Is data analysis credible and 
confirmable? 
  
16. Are the results presented clearly and 
appropriately? 
17. Are the results transferable and generalizable? 
18. Is the discussion comprehensive? 
19. Is the conclusion comprehensive? 
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assess studies for bias and this guidance was applied here for each of the 19 quantitative and 
18 qualitative items of Caldwell, Taylor and Henshaw’s (2005) framework:  
0 = Criteria not met/     1 = Criteria partially met    2 = Criteria fully met   N/A=Quantitative  
 Unable to determine         (Medium)   (High)    only questions
 (Low)       
 
A total score was calculated for each study, with a total potential score of 36 being available 
for qualitative studies and a total potential score of 38 for quantitative studies. All qualitative 
studies were case studies and so were not assessed against the framework for reasons 
discussed in detail below. 
A random sample of four quantitative studies, generated by computerised random number 
selection, was reviewed by a colleague from another discipline (nursing) who was familiar 
with the quality framework. The resulting disagreement level was 14% across items 9b, 11b, 
15b and 16. Upon discussion it became clear that these were the more subjective questions 
and appeared to be more influenced by previous experience and professional discipline than 
subjective judgment of the studies. A final score was allocated following discussion. 
Separating total scores into groups (e.g. high, medium or low) to identify levels of potential 
bias was considered, however no quality assessment framework or guidance could be found 
that supported this action and so studies are discussed in terms of level of quality on a 
continuous scale from the most to the least robust relative to one another (Table 3).  
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Table 3: Quality Assessment Framework in order of score  
 1 2 3 4 5 6 7 8 
9a 
9b 
10 
11a
11b 
12a
12b 
13a
13b 
14a
14b 
15a
15b 
16 17 18 19 Total 
Quantitative Studies 
7. Hadjivassiliou 
et al. (2003) 
2 2 2 2 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 36 
9. Hadjivassiliou 
et al. (2015) 
2 2 2 2 2 2 1 2 2 1 2 2 1 2 2 2 2 2 2 35 
12. Ihara et al. 
(2005) 
2 2 2 2 2 1 1 2 2 2 2 1 2 2 2 2 2 2 2 35 
8. Hadjivassiliou 
et al. (2006) 
2 2 2 2 2 2 2 2 2 0 1 2 2 2 2 2 1 2 2 34 
15. Pennisi et al. 
(2014) 
2 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2 1 2 1 34 
2. Cervio et al. 
(2007) 
2 2 2 2 2 2 0 2 1 0 2 2 1 2 2 2 2 2 2 32 
3. Cicarelli et al.  
(2003) 
2 2 2 2 2 2 1 2 2 0 2 2 1 2 2 2 1 2 1 32 
1. Alaedini et al. 
(2002) 
2 2 2 2 2 1 0 2 2 0 2 2 1 2 2 2 2 1 2 31 
21. Tursi et al. 
(2006) 
2 2 2 1 2 2 0 2 2 0 2 2 1 2 2 2 1 2 2 31 
5. Di Sabatino et 
al. (2015) 
2 2 2 2 1 1 0 2 2 2 2 1 1 2 1 2 2 2 1 30 
13. Lichtwark, et 
al. (2014) 
2 2 2 2 2 2 0 2 1 0 1 2 1 2 2 2 0 2 2 29 
4. Collin et al. 
(2008) 
2 2 2 1 1 2 1 1 2 0 2 2 1 2 2 2 1 1 1 28 
10. Hallert & 
Alstrom (1983) 
2 2 2 1 1 2 0 1 2 0 1 2 1 2 2 2 1 1 1 26 
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19. Souayah et 
al. (2008) 
2 2 2 1 1 2 0 0 1 0 2 1 0 1 0 2 0 2 2 21 
11. Hu et al. 
(2006) 
1 2 2 1 2 2 0 1 1 0 1 1 1 
 
0 1 1 0 2 1 20 
Note: Colour coding: High (green), Medium (yellow) and Low (red)
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The quality of the studies varied and according to the results from the quality assessment 
framework scores ranged from 20 to 36. In terms of patterns or aspects of quality, the 
majority of studies provided high quality introductions, abstracts and summaries to their 
content. There were two areas where there was a difference between the higher and lower 
quality studies, these were identification and justification of the methodology and the results 
being transferable and generalizable; studies achieving relatively lower scores consistently 
performed poorly against these criteria.  
Case studies were not interrogated against the quality assessment framework as they would 
necessarily perform poorly in measures of ability to generalise findings as well as others such 
as sampling method. Inclusion of these studies in the framework unfairly disadvantages case 
studies and so there is no advantage to including them. The framework was developed with 
the intention to provide a framework that evaluated health research that could then be put into 
practice and so it is correct that case studies perform poorly as they should not be used to 
develop clinical changes, certainly not on their own. The value of case studies is in the depth 
of information that they provide and as this is an exploratory review they provide further 
information that is valuable to discuss. Results of case studies will be discussed below with 
these considerations in mind.  
Areas where there were consistently lower scores on the quality framework were around 
ethical considerations and lack of experimental hypothesis. Where there was a mention of 
ethical factors, details were scarce or included only that research had been granted ethical 
approval and the name of the institution that had granted it. Given the symptomology 
associated with CD, NCGS and the nature of some participants’ symptoms this lack of 
consideration of, or at least reporting of, ethical issues was disappointing.  
Poorer quality studies increase the chance of bias in the results and caution needs to be taken 
when reporting such results. Two studies (11 & 19) performed poorly across all areas of bias 
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(Pannucci & Wilkins, 2010) and particularly poorly in terms of internal validity (Higgins et 
al, 2011) which is most likely to cause unreliable results. The risk of bias in the above two 
papers is so high and the likelihood of false results so probable they will not be discussed 
further in this review. Excluding the poorest quality studies ensures minimal data is lost, but 
also that the results reported are robust enough to inform the area of neurological and 
cognitive symptoms in adults with CD and NCGS. 
 
THEMES IDENTIFIED 
Neurological  
The neurological symptoms reported by adults with CD or NCGS are shown below (Table 4). 
The highest quality studies (7, 9 & 12) reported neurological symptoms of ataxia, slowed 
motor function, pain, poor balance, weakness, numbness and altered sensation in extremities 
and changes to the brain. Hadjivassiliou et al.’s (2003) participants had severe ataxia that 
required diagnoses or treatment by specialist services. This degree of severity was also found 
by Hadjivassiliou et al. (2006), which has comparable quality to the above studies. However, 
Pennisi et al. (2014) reported neurological examinations for all participants to be normal and 
Aleadini et al. (2002) reported only mild impairment (e.g. of nerve conduction). As all these 
studies performed highly on the quality assessment framework these differences are unlikely 
to be the result of bias. Indeed, this variation likely reflects the methods of recruitment in the 
above studies; Hadjivassiliou et al. (2003) and Hadjivassiliou et al. (2006) recruited from 
ataxia or neurology clinics, whereas Pennisi et al. (2014) and Aleadini et al. (2002) recruited 
from gastrointestinal or CD clinics, respectively. Being under the care of a neurology or 
ataxia clinic indicates more severe neurological symptoms are likely to be present at the point 
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of recruitment and would explain why these studies reported more significant levels of 
neurological symptoms. 
 
Table 4: Neurological symptoms in adults with CD and NCGS 
Study 
NCGS or 
CD 
Symptoms 
Reporting only Neurological results: - Cerebellar ataxia (unsteady gait and poor 
muscle coordination) 
- Slowed fine motor control 
- Pain 
- Dizziness and feinting 
- Poor balance 
- Numbness and pins and needles in hands and 
feet 
- Tingling in hands and feet 
- Muscle weakness 
- Encephalopathy (changes to the brain) 
- Slowed nerve response to stimulus 
- Reduced nerve response to stimulus 
- Electrophysiological changes in the motor 
cortex of participants with CD 
- Poor reflexes 
- Muscle rigidity 
- Visual problems 
- Paraparesis (partial loss of movement in all 
limbs) 
- Urine incontinence 
- Dysarthria (inability to produce clear speech) 
Hadjivassiliou et al. 
(2003) 
CD 
 
Hadjivassiliou et al. 
(2015) 
Both 
Hadjivassiliou et al. 
(2006) 
CD 
Cicarelli et al.  (2003) CD 
Alaedini et al. (2002) CD 
Tursi et al. (2006) CD 
Millington et al. (2015) CD 
Rigamonti et al. (2007) CD 
Souayah et al. (2008) CD 
Reporting Neurological and Cognitive 
results: 
Ihara et al. (2005) NCGS 
Pennisi et al. (2014) CD 
Cervio et al. (2007) CD 
Di Sabatino et al. (2015) NCGS 
Poloni et al. (2009) CD 
Stipic et al. (2002) CD 
Note: Studies and symptoms ordered by quality; light grey indicates poorest studies and so 
potentially less reliable symptoms 
 
 
High quality studies (1, 2, 3, 8, 15 & 21) additionally reported symptoms of slowed and 
reduced nerve response to stimuli, muscle weakness and poor reflexes. The central and 
peripheral nervous systems were both found to be affected (Cicarelli et al., 2003; Tursi et al., 
2006). Tursi et al. (2006) report that 38% of their adult CD participants reported signs of 
peripheral neurological damage and autonomic dysfunction (e.g. altered perception in 
extremities and recurrent fainting). Brain changes that would account for neurological 
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symptoms were not seen on CT (computerised tomography), but were shown by more 
sensitive nerve conduction tests. Comparable results were found in another study (Pennisi et 
al., 2014), where neurological examination was normal, however transcranial magnetic 
stimulation (TMS) found a pattern of brain activity that was unique to individuals with CD 
when compared to healthy controls. It is not clear whether the participants in this study 
reported any neurological concerns, however they were recruited consecutively as individuals 
with recent diagnoses of CD with no mention of experiencing neurological symptoms and so 
it is unlikely to have been an issue at the time of recruitment. Ihara et al. (2005) also 
identified the presence of motor neuropathy via nerve conduction studies.  
Studies that performed less well against Caldwell, Taylor and Henshaw’s (2005) quality 
assessment framework (4, 5, 10, 13 & 16) reported similar symptoms to those above. In fact, 
the only additional symptom reported is that of muscle rigidity (16); slowed motor function, 
pain and unusual sensations in hands and feet were all present in these studies, which makes 
them consistent with those symptoms reported in the higher quality studies. The case studies 
reported all previous symptoms, but also visual problems (14), paraparesis and urine 
incontinence (20), and dysarthria (19). The additional symptoms may be a result of the level 
of detail allowed in this methodological design that was not possible in other types of study. 
Also, case studies are more likely to be written (and published) when they are exploring new 
or unusual cases and so it follows that they may report symptoms that larger studies have not 
yet considered, for example, no other study other than that by Millington et al. (2015) 
considered visual acuity. 
Gluten ataxia (GA) is worth mentioning again here. Two studies investigating GA were 
captured by the search criteria used in this review (7 & 8) they were included as they met the 
inclusion criteria, however, this does complicate the interpretation of the studies’ findings as 
the neurological symptoms could be the result of GA rather than CD or NCGS, which is why 
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they have been discussed separately here. Hadjivassiliou et al. (2003) suggested that gluten 
sensitivity is the most common cause of idiopathic ataxia. GA occurs with and without CD 
and is a separate neuropathy that belongs under the umbrella of gluten sensitivities 
(Hadjivassiliou et al., 2003). Ihara et al. (2005) reported that individuals with ataxia (not 
defined in this study as GA) were more likely to be gluten sensitive than the general 
population. This study was carried out in Japan where CD is less than 1%, but suggested that 
gluten sensitivity is present in the population, just not in the form of CD. There are criticisms 
that can be levelled against these studies however, for example Ihara et al. (2005) did not test 
participants for CD or NCGS, which may act as confounding variables in the study. 
Similarly, Hadjivassiliou et al. (2003) did not consider the presence of NCGS in their 
participants. This lack of consideration of NCGS may be typical, but it still raises the 
question of whether the neurological symptoms reported in GA are related to NCGS rather 
than being a separate condition altogether. Currently the literature around the neurological 
and cognitive symptoms of CD and NCGS and the neurological symptoms of GA and 
possibly non-GA ataxia are not yet differentiated enough to confidently establish which 
symptoms are CD, NCGS, GA or something else.   
Overall, the neurological symptoms most consistently reported include unsteady gait, slowed 
motor control and altered sensation in extremities such as numbness or pins and needles. 
These findings are reported across both higher and lower quality studies. 
 
Cognitive 
There were fewer studies looking at cognitive symptoms (n=11) of CD and NCGS than those 
looking at the neurological symptoms (n=16). However, the majority of these studies scored 
well against the quality assessment framework (2, 4, 5, 10, 12, 13 & 15). NCGS was 
represented more equally in the cognitive studies compared to the neurological research 
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where the focus appeared to be on CD. The cognitive symptoms in adults with CD and 
NCGS are shown below (Table 5). 
There is disagreement between the highest scoring studies regarding the presence of cognitive 
symptoms. The highest scoring study (12) reported mild cognitive impairment in the areas of 
short term memory and word recall. While improvement of neurological symptoms was 
recorded following introduction of a GFD, the cognitive impairment was not reviewed. Thus, 
it was not possible to establish whether the identified mild cognitive impairment was 
responsive to a GFD, which may have suggested a link to NCGS. Pennisi et al. (2015) 
reported that participants with CD had normal cognitive function with no impairment and, 
although a less robust study, Hallert and Astrom (1983) also found no evidence of cognitive 
impairment in adults with CD. Participants did, however, report fatigue as a cognitive 
symptom (15), this was reflected by the poorest performing study against the quality 
framework (20) which presents a case study on a 47-year-old Croatian woman who 
experienced fatigue as a cognitive symptom of CD.  
The results of Cervio et al.’s (2007) research found evidence of memory and attention deficits 
in adults with CD, however this information was taken from participants’ self-reports rather 
than objective measurement. Despite this being a robust study, the focus was on the 
neurological symptoms and the investigation of cognitive symptoms was methodologically 
poor, which makes it difficult to rely on these findings. 
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Table 5: Cognitive symptoms in adults with CD and NCGS 
Study 
NCGS or 
CD 
Symptoms 
Reporting only Cognitive results: 
- Mild cognitive impairment (short term memory 
and word recall) 
- Tiredness/Fatigue 
- Normal cognitive function  
- Poor memory 
- Poor attention 
- Malaise 
- “Foggy mind” 
- Slowed processing speed, executive function 
(attention, sequencing and flexibility) and 
visuospatial memory 
- Alexithymia 
- Progressive frontal cognitive deficit 
- Loss of language 
Cervio et al (2007) CD  
Lichtwark et al. (2014) CD 
Collin et al. (2008) CD 
Hallert & Alstrom 
(1983) 
CD 
Reporting Cognitive and 
Neurological results: 
Ihara et al. (2005) NCGS 
Pennisi et al. (2014) CD 
Cervio et al. (2007) CD 
Di Sabatino et al. (2015) NCGS 
Poloni et al. (2009) CD 
Stipic et al. (2002) CD 
Note: Studies and symptoms ordered by quality; light grey indicates poorest studies 
 
Fatigue, malaise and foggy mind were reported by Di Sabatino et al. (2015). In this study 
participants completed a questionnaire assessing the frequency of these and other symptoms. 
After completion of each arm of the study these symptoms were re-assessed and found to 
increase following the ingestion of gluten. This is the first study in which cognitive 
symptoms were investigated pre- and post-intervention, for this reason these results are more 
robust.       
The complicated picture continues where the particular areas of cognitive impairment are 
reported. Ihara et al. (2005) identified verbal ability as an area of difficulty for participants 
with ataxia, whereas Lichtwark et al. (2013) found minimal (i.e. not significant) results in this 
area. Lichtwark et al. (2013) did find that removing gluten significantly improved 
performance on tests of processing speed, executive function and visuospatial memory, as 
measured by the subtle cognitive impairment test (Yelland et al., 2004), trail making tests A 
and B (Reitan & Wolfson, 1985) and the Rey-Osterrieth complex figure (Rey, 1941), 
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respectively. There is further disagreement as Ihara et al. (2005) report immediate and 
delayed recall (short term memory) is impaired and Lichtwark et al. (2013) found no 
evidence of a significant impact on memory. Poloni et al.’s (2009) case study reported 
“progressive…frontal cognitive deficit” (p. 2), but no further information was given as to 
how this diagnosis was made, however it can be understood as meaning impairment in 
executive functions (Otero & Barker, 2014), which supports the findings of high scoring 
studies (13).  
Collin et al. (2008) investigated the idea of a cognitive “coeliac profile” (page 1331), which 
was first suggested by De Rosa et al. (2004). This coeliac profile included the presence of 
alexithymia, which is described as having a cognitive and affective dimension (Van Der Veld 
et al., 2015). The cognitive dimension involves the inability to identify, describe verbally and 
analyse one’s own emotions. Collin et al. (2008) found the presence of alexithymia in only 
10% of participants in their study, which is the same as the prevalence in the general 
population. There was no evidence for the coeliac profile of alexithymia in gluten sensitive 
individuals. 
The variable methods used to examine cognitive ability, including: the Hasegawa dementia 
rating scale (Imai & Hasegawa, 1994; 12), the subtle cognitive impairment test (Yelland et al. 
2004; 12), and participant self-report (15 and others) may be partly the reason why the picture 
is unclear. Sensitivity of tests is also important. Neurological symptoms would often not be 
picked up by standard neurological examination or participant self-report, but were identified 
only when very sensitive tests were used. This may also be the case for cognitive symptoms 
and tests to identify suspected dementia (11) are unlikely to be sensitive enough (De Jager et 
al., 2009).  
Investigations of cognitive symptoms seem generally to be poorer than those of neurological 
symptoms. Even within high-scoring studies the results relating to cognitive symptoms can 
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be weak. There is no consistent set of tests used and no consistent agreement across the 
literature as to what areas of cognition, if any, may be affected in adults with CD or NCGS. 
However, from the results discussed above, short term memory, fatigue, executive function 
and processing speed were found in the most robust studies using objective measurements. In 
addition to this, these studies sought to explore the results of GFD on these symptoms and 
found that performance improved across these areas. This supports the notion that these 
symptoms are related to CD and NCGS as they reduce when these conditions are treated and 
well managed. 
 
Mechanisms of Damage 
The role of antibodies is well-established in CD and the presence of anti-gliadin antibodies 
(AGA) are an important indicator of diagnosis. Ihara et al. (2005) reported the presence of 
AGA is associated with more severe motor neuropathy in a group of non-CD participants 
when compared to non-CD patients without AGA. An area of particularly strong evidence is 
the involvement of anti-ganglioside or anti-neuronal antibodies (antibodies that react with 
cerebellar cells) in the sera of individuals exhibiting neurological signs of gluten sensitivity. 
Aleadini et al. (2002) reported that 20% of their participants were found to have these 
antibodies and all showed signs of neuropathy. As further support of the importance of these 
antibodies, Cervio et al. (2007) showed that sera taken from adults with CD and anti-neuronal 
antibodies caused apoptosis (cell death) in previously healthy human neurone cells. Tursi et 
al. (2006) found that 42% of their CD participants had anti-neuronal antibodies circulating in 
their blood, while Cervio et al. (2007) reported this figure to be closer to 50%. Taking even 
the higher figure into account, however, the presence of these antibodies alone is not a robust 
enough explanation for neurological damage.  
 37 
 
The role of inflammation as a mechanism of damage was not reported in these studies, 
however the mechanisms of damage were not the focus of the articles reviewed here and so 
this is not unexpected.  
 
Treatment Strategies 
The removal of gluten remains the only treatment strategy available for individuals who have 
CD or NCGS. Souayah et al. (2008) reported on the progress of three participants with ataxia 
who all showed reduction of neurological symptoms when treated with intra-venous 
immunoglobulin (IVIG). However, this study performed poorly against the quality 
framework across all areas of internal validity and the results need to be treated with caution.   
Neurological symptoms were found to vary in their response to a GFD. Alaedini et al. (2002) 
found there was no link between GFD and neurological symptoms, however did point out 
that a link cannot be ruled out just on the basis of their findings. Hadjivassiliou et al. (2006) 
found that only seral nerve conduction significantly improved following implementation of a 
GFD while no other measures of neuropathy did. Tursi et al. (2006) clearly demonstrated that 
there was no “remission” (page 1873) or change in the number or severity of neurological 
symptoms of participants with CD when following a strict, 12-month, GFD. The authors did 
state that there may be a negative correlation between the duration of gluten exposure before 
the onset of a GFD and symptom reduction, but this was not examined. Cicarelli et al. (2003) 
did find a significant correlation between duration of untreated CD and number of 
neurological symptoms. Hadjivassiliou et al. (2003) suggested that this relationship between 
untreated disease and number of symptoms demonstrates that neurological symptoms may 
initially be reversible, however extended exposure (not yet defined in the literature, but 
linked to symptom severity) leads to irreversible neurological symptoms. 
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Methodological Issues 
The quality framework used gave equal weighting to all items, which meant the accuracy of a 
paper’s title was as important as the data analysis used. Poor guidance was given as to how 
the more judgement-based criteria should be scored e.g. “Are the authors credible?”, which 
resulted in these items being more subjective as the decision was made by the reviewer. As 
shown by inter-rater comparison some of the questions were more subjective and influenced 
by previous professional approach. More guidance would help to develop a more objective 
rating system.  
Quality assessment frameworks can sometimes measure the quality of reporting rather than 
reflecting methodological bias, and the framework used here was written specifically for 
medical research. As the studies here were gathered from multiple-disciplines and countries 
reporting standards may have varied, and some may have scored lower due to these different 
standards rather than poorer designs or analyses.  
As mentioned previously, case studies would have scored poorly on some of the questions of 
this quality assessment framework. Although it is necessary for robust studies to be used to 
influence practice, it could mean that new and emerging issues – initially covered by case 
studies – are missed. It would be inappropriate for case studies to inform a developing 
evidence base, but it would be restricting for the data contained within them to be treated as 
too poor to be considered. 
There were a small number of papers that were unavailable to the author, usually due to there 
being no English translation. In two cases abstracts/outlines of the research had been 
published in journal supplements, but the full articles were not available. Whether they had 
yet to be accepted for full publication or were not yet complete is not known. This may have 
meant high quality studies were inadvertently excluded from this review. 
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The biggest complication with the evidence itself is the lack of recognition throughout of the 
impact of NCGS and refractory CD5 on the response to gluten. Studies measured adherence 
to a GFD via self-reports, which are known to have poor accuracy (Vitolins et al., 2000) and 
testing for the presence of AGA. In the studies discussed above data from participants who 
continue to have circulating AGA despite adherence to a GFD remain in the analysis. If these 
individuals are suffering from refractory CD their results may confound the findings as for 
them, damage may still be occurring. Individuals with NCGS may also respond differently to 
the removal of gluten as the mechanisms of the disease are different from that of CD and 
inclusion of individuals without screening for this condition may again give skewed results.  
There is likely to be an effect of the disciplines that have carried out the above research. This 
topic has very much straddled the medical and psychological literature and it may be more 
difficult than first thought to directly compare literature from the two schools. This may be 
why cognitive symptoms’ studies did less well against the quality framework. This is 
illustrated by the case studies; the wealth of information in these studies is vast, however the 
focus of the data varied widely depending on the epistemological background of the 
discipline. Not only this, but the interpretation of symptoms was also complicated by 
discipline. Stipic et al. (2002), for example, reported the symptom of fatigue, depending on 
the approach – medical or psychological – the interpretation of this symptoms could be 
neurological or cognitive. Fatigue is a self-report symptom with no objective test of 
assessment.  
The above point raises another issue, which is the sensitivity and specificity of the tests used 
to assess cognitive function. Of the studies that used and reported formal cognitive tests there 
                                                 
5 Refractory CD is defined as “the recurrence or persistence of malabsorptive symptoms and signs with villous 
atrophy despite a strict gluten-free diet for >12 months” (Ludvigsson et al., 2013; page 7). In a North American 
study (Rashan et al., 2011) reported 1.5% of individuals initially diagnosed with CD developed refractory CD.  
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was no agreement as to the tests used. Formal tests were designed to test a certain aspect of 
cognitive function rather than a general concept such as speed of nerve function. The internal 
validity of cognitive tests used may have affected the effectiveness of their results e.g. a test 
that measures planning may not be specific or sensitive enough to measure cognitive 
dysfunction as a result of gluten ingestion in adults with CD or NCGS. 
In summary, neurological symptoms of slowed nerve conduction, pain and altered perception 
in extremities can be accepted with confidence. They were found repeatedly across studies in 
both samples of patients with CD and NCGS. Neurological symptoms can be subtle and 
unnoticeable to the individual or severe; there does appear to be a dose effect based on 
duration of exposure to gluten and recovery on GFD depends on severity and duration of 
symptoms. The role of ataxia is not clear, although it is reported in the most robust studies, 
there are issues around whether NCGS was adequately ruled out in these samples. Fatigue 
and short-term memory can be most readily accepted as cognitive symptoms of CD and 
NCGS. There is agreement that cognitive symptoms reduce following a GFD. There does not 
appear to be any significant differences between CD and NCGS in terms of the types of 
symptoms experienced, which suggests the response to gluten molecules may be key rather 
than an autoimmune process. Unfortunately, this conclusion needs to be treated with caution 
and would require direct testing before it could be accepted with confidence. One of the 
reasons for this is the far larger number of studies that looked at CD than NCGS, which 
reflects the current state of the literature across these two conditions. 
 
CLINICAL AND RESEARCH IMPLICATIONS 
The clinical implications of the above review point to the importance of early diagnosis and 
treatment in both CD and NCGS to potentially prevent permanent neurological damage; 
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which initially at least, some individuals may not be aware of. The removal of gluten from 
the diet needs to be the priority, because, although findings are mixed as to the breadth of its 
effectiveness in terms of remission of symptoms or damage, a GFD is the only way to stop 
further damage occurring to the gut and neurology. 
Neurological examination is unlikely to be helpful in a true diagnostic setting as neurological 
changes seem to be, at least initially, subtle. It would however be beneficial to track any 
changes in more advanced neurological conditions such as ataxia following the introduction 
of a GFD. From the evidence above the only reliable way of doing this appears to be TMS 
and nerve conduction studies. Unfortunately, cognitively there are no tests that stand out as 
being sensitive enough at this time and tests to detect dementia are likely to be insensitive to 
very subtle cognitive changes. 
There is also a question as to whether ethically and/or clinically there is any reason to detect 
subtle changes to cognition and neurology. It is likely that subtle changes indicate shorter 
periods of gluten exposure, which will respond well to a GFD, but these are questions for 
further empirical study. 
There needs to be more robust research conducted on the cognitive symptoms of CD and 
NCGS, which would better inform and improve clinical practice. There may be a CD or 
NCGS cognitive profile that would enable health professionals to recognise these conditions 
without gastrointestinal symptoms and speed up the diagnosis and removal of gluten from the 
diet. 
There needs to be more investigation into the phenomena of NCGS and refractory CD as the 
literature is currently limited. There may be significant clinical implications for these groups 
of individuals that cannot be identified with the scarcity of information currently available. 
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The development of a NCGS ‘community’ with as much presence as the CD ‘community’ 
may help to further this agenda. 
Consideration should also be given of the impact of gluten on older adults and children. 
Although not in the scope of the current literature review the findings regarding the cognitive 
symptoms of adults with CD and NCGS are very relevant for younger and older people, 
especially when we remember that symptoms may present cognitively as opposed to gastro-
intestinally. Children struggling to do well at school, or older adults concerned about memory 
may in fact be experiencing issues related to CD and NCGS. 
In summary, the literature gives a clearer picture of the neurological symptoms found in 
adults with CD and to a lesser extent NCGS, the studies are generally more robust and there 
is more agreement across studies as to what the symptoms are, peripheral and central nervous 
system involvement is identified. It appears clear that symptoms can start very subtly and can 
become extremely severe. There is some opportunity to reduce or remove these symptoms, 
but the factors that enable this are not fully understood; however, duration of exposure to 
gluten, duration of symptoms and duration of GFD are likely to play a role. 
The picture of cognitive symptoms in adults with CD and NCGS is less clear. There is no 
overall agreement as to whether there are indeed any cognitive symptoms and certainly not 
which cognitive abilities are affected. The mechanisms of impairment are not discussed. 
There is a requirement for more research in this area and further attention and higher quality 
studies may start to clarify the picture. Anecdotally there is considerable agreement that there 
are significant cognitive effects for certain individuals, particularly within the CD community 
and this remains an interesting and exciting area for research. 
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GLOSSARY 
Alexithymia – An inability to recognise and describe your own emotions. Can impede ability 
to relate to and attach to others. Considered to have a cognitive and affective dimension.  
Antibodies – Cells (proteins) produced by white blood cells that are part of the immune 
response. Antibodies recognise and attack invading molecules within the body. 
Anti-ganglioside antibodies – Specific antibodies that react with cells in the brain. 
Anti-gliadin antibodies – Specific antibodies that react to gliadin, a protein found in wheat. 
Autoimmune – When the body’s immune response mistakenly targets the body’s own 
healthy cells. Different autoimmune diseases attack different cells. Cause of autoimmune 
diseases generally unknown, although genetic factors play a role in many. 
Cytokines – Are produced by cells involved in an immune response. They cause other cells 
to behave in certain ways e.g. to target an invading virus or bacteria. 
Guillian Barre syndrome – A rare autoimmune condition where the body attacks its own 
nerves. Weakness, numbness and tingling are common symptoms and can lead to paralysis if 
untreated. 
Immunoglobulin (IG) – A concentrated form of natural human antibodies, usually used to 
treat individuals with compromised immune systems. 
Motor cortex – An area of the frontal lobe if the brain that is involved with the planning, 
control and carrying out of voluntary movement. 
Motor neurone disease – Is a term used for a number of conditions that share the 
characteristics of affecting the parts of the nervous system (brain and spinal cord) that control 
the movement of muscles. It is progressive and symptoms get worse over time from 
weakness to a total inability to move.  
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Moyamoya disease – A rare and progressive disease that is characterised by multiple, small 
blockages of the arteries at the base of the brain. The name means “puff of smoke”, which 
describes the look of the multiple small blood vessels that stem from the blockage to provide 
blood to the area affected. 
Neuropathy – Damage or dysfunction of any of the nerves that make up the peripheral 
nervous system. 
Occipital lobe – The area of the brain that is responsible for vision. 
Transcranial magnetic stimulation (TMS) – In this case is a method to detect and diagnose 
dysfunction in motor nerve conduction using magnetic pulses delivered painlessly to the 
head. 
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ABSTRACT 
Aim 
The aim of this research is to investigate the moderated mediation effects of self-efficacy and 
coping style on the indirect relationships between illness perceptions and psychological 
wellbeing and quality of life in a sample of UK adults diagnosed with the autoimmune 
condition coeliac disease.  
 
Method 
The study follows an online, cross-sectional, questionnaire-based design, which gathered 
information from the sample (n=1578) at one time point. Data were collected on illness 
perceptions (IPQR), wellbeing (DASS21), quality of life (CDQ), dietary adherence, coping 
(Brief COPE) and self-efficacy (ASES) alongside demographics and information specific to 
coeliac disease diagnosis and management.  
 
Results  
Psychological wellbeing is best moderated and mediated via emotion focussed and 
dysfunctional coping for all illness perception sub-scales, other than personal control. Quality 
of life is more complicated, but significant moderated mediation routes were found through 
dysfunctional coping for all CDQ subscales, through emotional focussed coping for CDQ 
emotion and through problem focused coping for CDQ social and CDQ diagnosis and 
treatment worries.  
 
Conclusion 
This study shows that higher self-efficacy for the dietary management of coeliac disease 
leads to the reduction of dysfunctional coping strategies; using adaptive strategies improves 
psychological wellbeing and quality of life. Assessing self-efficacy following a diagnosis of 
coeliac disease could be helpful in identifying individuals who may struggle to manage their 
condition and achieve good outcomes. Alongside this, supporting the development of more 
adaptive and less dysfunctional coping strategies will improve outcomes and further increase 
self-efficacy, psychological wellbeing and quality of life.   
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INTRODUCTION 
Coeliac Disease 
Coeliac disease (CD) is a chronic autoimmune condition triggered by the ingestion of gluten 
in genetically susceptible individuals (NICE, 2015). Gluten causes the villi, hair like 
structures in the intestines, to become flattened. This reduces the surface area of the gut and 
reduces its ability to absorb nutrients from food, which can cause further issues; anaemia 
(Freeman, 2015) and osteoporosis (Scott, 2000). There are a wide range of symptoms 
associated with CD.  Gastrointestinal symptoms include bloating, diarrhoea, constipation and 
abdominal pain (Hadjivassiliou et al., 2016). Extra-intestinal effects include fatigue 
(sometimes referred to as “brain fog”) (Yelland, 2017), nervous system abnormalities 
(Hadjivassiliou et al., 2006) and skin conditions (Coeliac UK). Individuals with the condition 
may suffer a variety of these symptoms or may not be aware of any (Iwańczak et al., 2013); 
receiving a diagnosis after investigations for other conditions such as anaemia or unexplained 
weight loss (Green et al., 2005).  
CD is diagnosed via blood tests followed by confirmatory intestinal biopsy if CD-specific 
antibodies are present or if symptoms persist (NICE, 2015). A life-long gluten free diet 
(GFD) is the only treatment for CD. Ingesting even 100ppm (parts per million) of gluten will 
cause intestinal damage to continue (Collin et al., 2004). Foods must be < 20ppm to be sold 
as “gluten free” (Codex Standard 118-1979, 2015). A strict GFD allows the intestines to heal 
(Collin et al., 2004; Rubio-Tapia et al., 2010) and within 12 months most individuals with 
CD will be symptom free (Galli et al., 2014); absorption can return to normal and symptoms 
disappear (Corbett et al., 2012). Each individual reacts to gluten ingestion differently in terms 
of duration of and severity of symptoms (Coeliac UK). 
CD is the most frequently diagnosed food-related disorder in Europe (Baiardini et al., 2012), 
effecting around 1% of adults (Woodward, 2015); even so it is thought to be significantly 
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underdiagnosed (NICE, 2015; Coeliac UK; Hopper et al., 2007). Rates vary throughout the 
remainder of the world in relation to the amount of gluten-containing food in the national 
diet. The UK, USA and Europe consume a lot of gluten rich foods as dietary staples, whereas 
in other countries rice is the staple carbohydrate; CD is found in fewer than 0.05% of 
Japanese adults (Mai et al., 2017).  
There are a number of factors that affect adherence to a GFD. These include understanding 
the requirements and being a member of a supportive CD-specific network (Leffler et al., 
2008). Not only do these factors influence the ease with which people can follow a GFD, they 
also influence quality of life. In a Canadian adult sample, Zarkadas et al. (2006) reported that 
the quality of life of individuals with CD was related to dietary support and availability of 
gluten free foods. They also reported that when participants experienced improvement in 
symptoms it encouraged them to follow the GFD. Depression and anxiety can frequently be 
experienced by people with CD (Addolorato et al., 2004). The reasons for this are 
complicated and Sverka et al. (2005) qualitatively investigated exactly what could cause 
psychological distress by interviewing 43 adults with CD. They found a number of complex 
factors across three categories; the emotions related directly to having CD, interpersonal 
difficulties around the requirements of the diet, and risk-taking. Additionally, gluten-free 
foods remain substantially more expensive than their gluten-containing counterparts placing a 
further burden on individuals with CD (Lee et al., 2007; Missbach et al., 2015).  
Psychological and behavioural factors play an important role in the management of chronic 
conditions. An understanding of the illness, treatment and outcomes are key in understanding 
how choices are made and what outcomes may be achieved. They also help in pointing to the 
focus of interventions if there are difficulties in keeping to a health regimen. 
 56 
 
Illness Perception 
Leventhal et al.’s (1980; Meyer et al., 1985) Common Sense Model of self-regulation (CSM) 
was developed to explain why people make, or do not make, health-related decisions. Illness 
was understood as a threat that induced fear, however it was found that people needed several 
types of information for their beliefs and actions to be influenced, not just fear of illness. 
Other theories sought to do the same, however the CSM was the first to combine cognitive 
and emotional factors and to model these as parallel processes for the individual (Huston & 
Houk, 2011). The CSM states that when an individual becomes unwell, the way in which 
they understand and perceive their illness effects the way they cope with it (Huston & Houk, 
2011) and this then influences the way they manage the illness and effects the outcomes they 
achieve (Brownlee et al., 2000). Hale et al. (2007) describe the 3-stage process of illness 
perception described by Leventhal et al. (1980); the initial understanding, or representation, 
of the illness and what this means, the planning and taking action phase of managing an 
illness and a final phase where the effectiveness of the strategies used so far is reviewed by 
the individual. Initially there were five components; identity, consequences, timeline 
(acute/chronic), control/cure and cause (Weinman et al., 1996); more recently these factors 
were analysed and revised to the eight now included in the Illness Perception Questionnaire – 
Revised (IPQR), identity, timeline (acute/chronic), timeline (cyclical), consequences, 
personal and treatment control, illness coherence and emotional impact (Moss-Morris et al., 
2002). Individuals who reported more perceived control experienced less distress (Gonzalez 
et al., 2015) and were better at adhering to the requirements of managing their illness (Ford et 
al., 2012). Huston & Houk (2011) found that young adults with well controlled type 1 
diabetes discussed the emotional impact of their condition, had greater acceptance and greater 
illness coherence than young adults with poorly controlled type 1 diabetes. Illness 
perceptions have been shown to be significant in many chronic conditions (Zelber-Sagi et al., 
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2017; Langston et al., 2017) and meta-analyses have reflected similar findings (Broadbent et 
al., 2015, Hagger & Orbell 2003; Hagger et al., 2017). 
Illness perceptions are important determinants of behaviour (Petrie et al., 2007) and have 
been found to predict certain outcomes such as depression and anxiety (Costa et al., 2015) 
and health related quality of life (Rochelle & Fidler, 2012) in chronic and autoimmune 
conditions respectively. 
 
Psychological Wellbeing 
One of the outcomes in this study is psychological wellbeing. Psychological wellbeing can be 
difficult to define (Dodge et al., 2012), however for this study it is understood to mean the 
absence of symptoms of psychological illness such as anxiety and depression. The interaction 
between psychological wellbeing and health has long been an area of research (Das, 2016; 
Pratt et al., 2015). Park et al. (2013) reported symptoms of depression to be linked to long-
term outcomes, including mortality, in diabetes. Wellbeing, indicated by factors such as joy, 
happiness and contentment, can positively impact health and longevity (Chida & Steptoe, 
2008). Ironson et al. (2017) looked at wellbeing, health behaviours and biomarkers of cardiac 
illness and found a relationship between reduced C-reactive proteins – biomarkers of 
inflammation - and positive wellbeing.  
In terms of CD research, Barratt et al. (2011) found that depression and anxiety were 
correlated with poorer perceived adherence to a GFD. Brands et al. (2004) found the impact 
of the dietary restrictions required to remain healthy have a negative impact on psychological 
wellbeing. Adults with CD have poorer reported wellbeing and score worse on measures of 
anxiety, general health and vitality (all measured by the Psychological General Wellbeing 
Index) than the general population (Baiardini et al., 2012). Depression has a larger impact on 
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subjective wellness than the presence and severity of gastrointestinal symptoms (Sainsbury et 
al., 2013) and affects adherence to the GFD. However, Van Hees et al. (2013) found that 
longer term adherence to a GFD reduces depressive symptoms. This possibly points to a 
relationship between wellbeing and other factors such as self-efficacy, which will be 
discussed later. 
 
Quality of Life 
The second outcome in this study is health related quality of life. While quality of life and 
wellbeing are sometimes used to describe the same construct (Frisch et al., 1992), quality of 
life describes a wider set of factors that includes psychological, physical and social 
considerations (Cooke et al., 2016). Health related quality of life (HRQOL) is defined as the 
“way health is empirically estimated to affect quality of life” (Karimi & Brazier, 2016; pg 
648). Assessing health related quality of life (HRQOL) is a key area for health research 
including oncology (Cella & Stone, 2015), paediatrics (Baumann et al., 2015) and weight 
management (Minet Kinge & Morris, 2010).  
Katsanos et al., (2016) found that HRQOL (measured by the EQ-5D; Group E, 1990) varied 
depending on which technique was used to surgically treat cardiac disease. Wound healing 
was also more rapid for the higher HRQOL group; however, it was not possible to establish 
the direction of this relationship. Mishra et al., (2015) reported that adults who were 
undergoing cancer treatment experienced increased HRQOL if they engaged in a moderate, 
regular exercise program. Ayis et al., (2015) found that higher HRQOL predicted survival 
past one year in adults and older adults who had experienced stroke. HRQOL may improve 
clinical outcomes across a number of acute or chronic conditions. 
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Hauser et al., (2007a) found European studies generally reported that individuals with CD 
had lower HRQOL, while American and Canadian studies reported levels comparable with 
the general population. HRQOL is more important than disease severity in determining CD 
patients’ level of distress (Dorn et al, 2010). 
Considering the second phase of the CSM, illness perceptions are used to predict the coping 
strategies that are likely to be used by individuals. This is discussed in detail below. 
 
Coping 
Another area  for consideration is that of coping and how different strategies may predict 
different outcomes in long-term conditions (Hagger & Orbell, 2003). In Drossman et al.’s 
(2000) study, higher scores on the catastrophising scale and lower scores on the ability to 
decrease symptoms scale (Coping Strategies Questionnaire) in women with gastrointestinal 
disorders predicted poorer health outcomes and higher neuroticism. Lawson et al., (2007) 
found that adults with diabetes who regularly attended health-management clinics used more 
adaptive coping strategies than those who did not attend. 
German and Austrian adolescents rated their own adherence to a GFD; those who reported no 
gluten consumption each month were classed as “compliant”, all others were “non-
compliant”. Wagner et al., (2016) found compliant adolescents were less likely to use 
emotional regulation and distraction strategies. Dowd and Jung (2017) examined self-
compassion as a coping strategy in North American adults with CD and the impact this may 
have had on adherence to the GFD. The study reported that participants who were self-
compassionate had better HRQOL and better dietary self-management. Self-compassion can 
be interpreted as being related to positive emotional coping, or opposite to dysfunctional 
coping, which includes self-blame (Carver, 1997). 
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Optimism is associated with positive coping strategies and better health outcomes in 
individuals with chronic conditions (Fournier et al., 2002; Fournier et al., 2003). Karademas 
et al. (2011) found that pre-CD diagnosis optimism mediated illness outcomes using the 
CSM; more optimistic participants used more adaptive coping styles. This study also 
highlighted the importance of an illness perception “feedback loop” (page 568) in which 
effective coping strategies feeds back and impacts illness perceptions causing them to 
become more positive and less negative. This demonstrates Hale et al.’s (2007) final stage of 
the CSM. In more self-efficacious individuals using adaptive coping strategies, may result in 
a similar feedback loop as they experience less symptoms of CD and more confidence in their 
own ability to manage the disease. 
 
Self-Efficacy 
Self-efficacy is the idea that a person needs to believe in their ability to take action to achieve 
a goal before they start to take action (Bandura, 1997). Bandura (1994) explained that self-
efficacy increased as a result of previous effective behaviour. Self-efficacy has been shown to 
play an important role in the maintenance of healthy choices such as exercise (Higgins et al., 
2014) and smoking abstinence (Hoeppner et al., 2014) and is important to consider in the 
context of CD given that ongoing commitment to a GFD is vital. Improving self-efficacy 
through targeted interventions (McCarroll et al., 2014) has been shown to improve health 
outcomes such as weight loss following cancer treatment. 
Schwarzer & Renner (2000), however, found that high self-efficacy alone is not sufficient to 
explain positive health decisions in healthy adults. Individuals also need to hold outcome 
expectancies linked with the behavioural change being undertaken. This was reflected in the 
results of Nouwen et al., (2009) who reported that dietary self-efficacy combined with short-
term treatment effectiveness was a significant predictor of dietary adherence in individuals 
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with diabetes. When individuals with CD choose to consume gluten containing foods, low 
self-efficacy has been found to be a reliable predictive factor (Hall et al., 2013). 
While the evidence that self-efficacy is strongly related to health outcomes is robust, the 
direction of this relationship is not so clear (French, 2015). Many studies identify a link, but 
the methods and models used do not allow identification of whether high self-efficacy comes 
before or as a result of achieving a goal. 
 
Moderated Mediation 
In order to examine the complex relationships between the factors effecting health outcomes 
moderated mediation models are frequently used as they allow multiple variables to be 
considered within the same analysis. Hofer et al. (2017) investigated multiple moderators 
such as age, gender and self-efficacy on medication adherence in adults with diabetes and 
found that significance was not reached for any of the moderators used. The significant 
mediator was satisfaction with medication information, which improved medication 
adherence. Varni et al. (2017) found that perceived medication adherence barriers in patients 
with gastrointestinal symptoms moderated health related quality of life. This was further 
mediated by patient communication, meaning that when patients were able to effectively 
communicate with their healthcare providers the perceived barriers had less effect on quality 
of life. 
This is a complex area and a number of relationships are possible between all the aspects 
discussed above, which need to be carefully considered and modelled. For the purpose of this 
study the CSM provided a model and basis of understanding for the outcomes of 
psychological wellbeing and HRQOL for adults with CD. The CSM states that illness 
perceptions predict coping and within this study coping is used as a mediator for the 
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outcomes. Level of self-efficacy is explored as a moderator, as different levels of self-
efficacy may lead to a difference in individuals’ ability to utilise coping strategies, which 
may in turn affect psychological wellbeing and HRQOL. Following existing precedent in 
health research a moderated mediation model was used to allow examination of these factors.  
Aim 
The aim of this study was to investigate whether there were relationships between illness 
perceptions, psychological wellbeing and quality of life and whether these relationships were 
mediated by coping and moderated by self-efficacy for the GFD in adults with CD. 
 
Hypotheses 
Hypothesis One:  
There will be a relationship between illness perceptions and the outcomes (a & b) as illness 
perceptions become more negative (e.g. belief in long-term, serious consequences of CD) 
outcomes will reduce. 
a) psychological wellbeing  
b) quality of life 
 
Hypothesis Two: 
There will be a relationship between illness perceptions and coping strategies. As illness 
perceptions become more negative (e.g. belief in long-term, serious consequences of CD) 
more dysfunctional coping strategies will be used. 
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Hypothesis Three: 
There will be a relationship between coping strategies and the outcomes (a & b). As more 
dysfunctional coping strategies are used outcomes will reduce. 
 
Hypothesis Four: 
The relationship between illness perceptions and the outcomes (a & b) will be mediated by 
coping strategies 
 
Hypothesis Five: 
Dietary self-efficacy will moderate the mediation of coping strategies on the relationship 
between illness perceptions and the outcomes (a & b) 
 
METHOD 
The data described below were collected for an exploratory study funded by Coeliac UK and 
carried out by researchers within the School of Psychology, University of Birmingham 
between 2009 and 2010.  Preliminary, descriptive data analyses were included in an end of 
grant report but the data had not otherwise been analysed. 
 
Participants 
Participants were recruited via the Coeliac UK website and by advertising on a popular and 
well-established CD Facebook page. The study was further promoted through the Coeliac UK 
members’ magazine. Data were gathered through an online questionnaire pack (Appendix A) 
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hosted by Survey Monkey. If preferred participants were able to request paper copies of the 
questionnaire pack. In this case, completed questionnaire packs were returned to the 
University of Birmingham in pre-paid envelopes. 
 
The following inclusion criteria were a requirement of participation: 
1. A self-reported diagnosis of CD (made by either blood test and biopsy or blood test 
alone) 
2. Adults aged over 18 years 
3. A UK resident at the time of the survey 
 
In total 1672 participants logged in to start the survey with 1410 participants (84%) 
completing and submitting the online pack. In addition, 262 requests were made for paper 
copies and 218 (83%) of those were returned. Following data collection, participants with 
more than 25% missing data across all measures were excluded from analysis; this resulted in 
a final sample of 1578 participants. Participants with < 25% missing data were included and 
missing data values were dealt with as appropriate for each stage of analysis as described 
below. 
The ages of participants ranged from 18 – 85 years with a mean of 47 years (SD 14.29); 1228 
respondents were female (83%) and 259 were male (17%). Most of the participants were 
‘White British’ (n=1383, 94%), 5% identified as ‘White Other’ and less than 1% (n=25) as 
other ethnicities (‘Asian’, ‘Black’, ‘Mixed - White and Asian’, ‘Mixed - White and Black’). 
Additional participant demographics below (Figure 1). 
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Figure 1: Participants’ highest educational level and marital status 
 
Design 
The study follows a cross-sectional, questionnaire-based design. Data were collected on 
illness perceptions, wellbeing, quality of life, dietary adherence, coping and self-efficacy 
alongside demographic information and information specific to CD diagnosis and 
management.  
For the purposes of the current analysis, the predictor variable is illness perceptions (x); 
dependent variables (y) are psychological wellbeing and quality of life, coping is a mediator 
(m) and self-efficacy acts as a moderator (w).  
 
Ethical Approval 
Ethical approval was received from the University of Birmingham Human Research Ethics 
committee in 2008 before data was collected (Appendix B). 
Highest Educational Level
School only (5%)
School with qualifications (31%
University (31%)
Postgraduate (19%)
Vocational training (14%)
Marital Status
Single (16%) Co-habiting (12%)
Married (63%) Divorced (5%)
Separated (2%) Widowed (2%)
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Materials 
Participants completed questionnaires to assess each area. A summary of these are presented 
below: 
• The Illness Perceptions Questionnaire Revised (IPQR: Moss-Morris et al., 2002) is 
a 58-item scale that assesses individuals’ beliefs about their illness across eight 
subscales of identity, timeline acute/chronic (α= .89) or cyclical (α= .79), 
consequences (α= .84), personal control (α= .81), treatment control (α= .80), illness 
coherence (α= .87) and emotional representations (α= .88). There is a further subscale 
that assesses participants’ attributions of the cause of their illness. As is not 
uncommon in research regarding specific diseases (Baiardini et al., 2012; Karademas 
et al., 2011) this subscale was not included.  
- Higher scores indicate strong agreement with each subscale. 
• The Depression Anxiety Stress Scale 21 (DASS21: Lovibond & Lovibond, 1995) 
contains a total of 21 items (α= .88), seven each for depression (α= .72), anxiety (α= 
.77) and stress (α= .70). High scores on the depression measure map onto mood 
disorders, high scores on the anxiety measure correspond to panic disorder and high 
scores on the stress scale are associated with generalised anxiety (Brown et al., 1997). 
- Higher scores indicate poorer psychological wellbeing.   
• The Coeliac Disease Questionnaire-Health Related Quality of Life (CDQ: Hauser 
et al., 2007b) is a 28-item scale developed to specifically examine health related 
quality of life in individuals with CD across four subscales; gastrointestinal symptoms 
(α= .80), emotional impact (α= .91), social impact (α= .81) and worries related to the 
disease (α= .81). 
- Higher scores indicate higher quality of life. 
• The Brief Coping Orientation to Problems Experienced (Brief COPE: Carver, 
1997) is a 28-item version of the full COPE inventory (Carver et al., 1989), which is 
divided into 14 sub-scales; self-distraction (α= .71), active (α= .68), denial (α= .54), 
substance use (α= .90), emotional support (α= .71), behavioural disengagement (α= 
.65), venting (α= .50), instrumental support (α= .64), positive reframing (α= .64), self-
blame (α= .69), planning (α= .73), religion (α= .82), humour (α= .73) and acceptance 
(α= .57). These subscales are condensed into three; problem focussed coping, emotion 
focussed coping and dysfunctional coping (Cooper et al., 2008). 
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- Higher scores indicate more use of these coping strategies.  
• Adult Self-Efficacy (for the Gluten Free Diet) Scale (ASES: Based on Senecal et 
al., 2000) is a 34-item scale that measures self-efficacy in maintaining a GFD when 
faced with a number of scenarios. 
- Higher scores indicate higher self-efficacy for the GFD. 
• Gluten Free Diet Questionnaire is a 6-item measure written by the original research 
team. It asks participants to report how often in the last two weeks they have 
knowingly eaten gluten and how well they stick to their GFD both at home and away 
from home. Participants also report how concerned they are about gluten exposure 
and how harmful they think it is. 
- Responses were given on a 5-point Likert scale, higher scores indicate poorer 
adherence to the GFD and more concern about the danger of gluten. 
 
Participants and Procedure 
A licence was purchased from Survey Monkey to enable online data gathering. Prior to the 
public launch the online site was tested for ease of access, ease of use and technical issues by 
the research team.  
Staff at Coeliac UK provided their advice and support regarding the design of the online 
materials and recruitment of participants both before and during data collection. 
Informed consent was gathered for all participants at the first stage of the questionnaire. 
Participants read and agreed to consent to the study before they were given access to the 
questionnaire pack. 
Confidentiality was explained and maintained by assigning participant numbers to each 
completed questionnaire. No personal data were included in the database. 
When the project was launched in October 2009, potential participants were provided with 
online links to the survey pack. All the information regarding the research and consent were 
included in this link. After reading the project information sheet participants who were happy 
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to continue gave their consent online. They could then complete the online questionnaire 
pack or request a paper copy.  
The online survey was closed on 30th September 2010; no further paper questionnaire packs 
were sent out after this date, although completed packs received afterwards were included. 
The initial response was huge, with over 800 online questionnaire packs being completed 
within the first five weeks.  
For the purposes of the initial study an end of study report was produced in May 2011. This 
provided mainly descriptive information of the data gathered and the participants who took 
part. 
 
Analysis 
Data were initially coded and input into SPSS by the original research team. The author 
completed data “cleaning” or screening of data for errors and potential coding mistakes; 
unknown coding strategies were treated as missing data. Following this, detailed statistical 
analysis of the dataset was completed using SPSS (IBM SPSS Statistics version 23) as 
described below. 
The demographic information was examined using frequencies and descriptive statistical 
techniques which provided information on age, gender, ethnicity, education level, history of 
CD diagnosis and management.  
Data were examined for normality using Kolmogorov-Smirnov to indicate whether they 
violated the assumptions for parametric analysis.  
Running analyses with missing data can bias results and reduce statistical power (Zhang & 
Wang, 2013). Missing items were analysed across scales to examine whether absent data 
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followed random or non-random patterns using SPSS’s Missing Values Analysis. Non-
random missing data patterns were excluded from further analysis. 
Missing values were imputed for all items of missing data using 10 multiple imputations. 
Pooled multiple imputation data was used to describe means and standard errors for each 
subscale. Inter-correlations were completed where appropriate. The effects of gender and 
time since diagnosis were also considered through correlation and Mann-Whitney U tests. 
Final hypothesis testing was carried out using the LAVAAN package of R Studio (R Studio 
Team, 2015) combined with a project-specific program written by Dr Chris Jones (University 
of Birmingham) to allow a full information maximum likelihood version of Hayes (2013) 
Model 7 to be analysed; the reason for this is discussed further below. No other program 
existed to enable this analysis to be completed. 
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RESULTS 
Further Demographic Information 
Sixty-five per cent (n=1029) of the sample reported they were diagnosed with CD following 
blood tests and biopsy with a further 20% (n=316) reporting they were diagnosed through 
biopsy alone. Duration of diagnosis ranged from < 6 months to 67 years with a mean of nine 
years three months (SD=10.47). Of the participants who answered the question relating to the 
results of their last blood test most had normal antibody results (n=592, 46%), some could not 
remember (n=365, 28%) and the rest were abnormal (n=287, 22%); 38 participants had not 
had a blood test. 
Five hundred and ninety-six respondents (38%) reported other health conditions, of these 216 
(57%) had thyroid disease, 187 (31%) had asthma, 58 (10%) had heart disease and 25 (4%) 
type 1 diabetes. Other food intolerances were also present in 23% of respondents. The most 
common of these were intolerance to dairy (n=140, 39%), caffeine (n=47, 13%), alcohol 
(n=37, 10%), yeast (n=19, 5%) and fructose (n=11, 3%) respectively. Other food intolerances 
were reported by 107 participants. Participants were asked to rate how well they followed 
their GFD at home and away from home (GFD Questionnaire). In this sample participants 
reported being extremely good at following their GFD with 95% (n=1438) reporting they had 
been exposed to gluten fewer than twice in the last two weeks while at home and 93% 
(n=1413) reporting the same while away from home. There was a small, but not significant 
difference between ability to stick to a GFD when at home or away from home with 
participants reporting 97% (n=1472) and 92% (1392) respectively. Most participants were 
‘extremely’ concerned by the prospect of accidental gluten ingestion (n=465, 31%), however, 
most frequently reported accidental ingestion of gluten was ‘quite’ (n=772, 51%) or ‘a little’ 
(n=715, 47%) harmful.  
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Missing Data 
If statistical analyses were performed only on datasets without missing data then this would 
result in a significant reduction in sample size (i.e., to approximately 60% of the original 
sample for some variables). This loss of data would, in itself, constitute a significant bias to 
further statistical analysis. Therefore, treatment of missing data needs to be considered prior 
to statistical analysis in all research (Zhang & Wang, 2013), not dealing appropriately with 
missing data can ultimately result in weak or incorrect conclusions (Little & Rubin, 2002) 
and will produce bias.  
Missing data were analysed to identify whether there were any patterns in the missing data 
that suggested that certain questions were systematically not answered i.e. not missed at 
random. These patterns of missing data (Little & Rubin, 2002) may bias results if it is 
assumed all missed data points occurred at random when they in fact did not. The table below 
(Table 1) shows the results of this analysis. 
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Table 1: Missing data patterns by variable 
Measure  
(Variable) 
Summary of missing data Pattern Analysis Action 
IPQR 
Across 36 (98%) items in 
the variable 124 (< 1%) 
values were missing from 
66 (4%) cases 
Random missing 
data patterns 
identified 
Replace missing data 
using multiple 
imputation 
ASES 
Across 100% of items in the 
variable 2061 (4%) values 
were missing from 698 
(44%) cases 
Non-random 
missing data pattern 
identified – Question 
5 was systematically 
not answered 
Remove ASES question 
5 from further analysis 
CDQ 
Across 100% of items in the 
variable 1526 (3%) values 
were missing from 393 
(25%) cases 
Random missing 
data patterns 
identified 
Replace missing data 
using multiple 
imputation 
Brief 
COPE 
Across 100% of items in the 
variable 1946 (4%) values 
were missing from 243 
(15%) cases 
Random missing 
data patterns 
identified 
Replace missing data 
using multiple 
imputation 
DASS21 
Across 100% of items in the 
variable 1658 (5%) values 
were missing from 199 
(13%) cases 
Random missing 
data patterns 
identified 
Replace missing data 
using multiple 
imputation 
Note: IPQR Illness Perception Questionnaire – Revised, ASES Adult Self-Efficacy Scale, CDQ Coeliac 
Disease Questionnaire – Health Related Quality of Life, Brief COPE Brief Coping Orientation to Problems 
Experienced, DASS21 Depression Anxiety and Stress Scale 21 
 
 
 
A number of methods to deal with missing data were considered such as list-wise (LW) and 
pair-wise (PW) deletion, however, although these remain common methods (Chen et al., 
2005) Zhang & Wang (2013) point out that they have not been specifically examined in terms 
of their performance in moderated mediation models. There are other issues with using these 
methods such as assumptions about the data (LW) and that analysis might be based on 
different samples (PW). Mean substitution (MS) was rejected as there is a risk that bias 
would be produced (Malhotra, 1987) as a result of the means replacing the missing data not 
being random. 
Multiple imputation (MI) is not affected by the issues raised above. According to the 
literature MI is superior to PW, LW and MS (Kang, 2013; Zhang & Wang, 2013; Baldwin et 
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al., 2016) particularly with large samples. MI does not distort the original data (Mercer et al., 
2011), whether it was skewed or normally distributed.  For these reasons, it was chosen here 
and used in all analysis below unless stated otherwise. 
 
Multiple Imputation 
An important consideration therefore is how many imputations to use. Initially guidance 
based on Rubin’s (1987) formula suggested that five to 10 imputations were enough, 
however, this focussed on efficiency, but not, as highlighted by Allison (2012), standard error 
estimates, confidence intervals, and p-values. Graham et al. (2007) recommends a higher 
number of imputations dependent on how much missing data are present. Using this 
guidance, 10 imputations were used (Graham et al., 2007; Bodner, 2008). Many statistical 
packages use 100 imputations as standard, however the use of such a considerable number 
adds nothing to the strength of the outcome and is not necessary (Allison, 2012). All further 
analyses present the results of pooled multiple imputation unless otherwise stated. 
 
Normality of distribution 
The Kolmogorov-Smirnov test indicated results across all measures were skewed from 
normal. This is not unusual in health research (Pallant, 2007; Baldwin et al., 2016) and in this 
case, is particularly likely as the inclusion criteria required participants to have a diagnosis of 
CD which increases the likelihood that responses to CD-related questions would be skewed.  
 
Internal Consistency 
Overall, across all subscales, all alpha levels were acceptable or better and only three were 
questionable or poor (Table 2). Removal of items within these lower scoring subscales would 
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not significantly increase the alpha level and no items were removed. Subscales with 
reliability below 0.6 (grey in table) were excluded from further analysis as they held too 
much risk of biasing the results and causing errors.  
Table 2: Internal consistency values by subscale 
Measure 
Internal 
Validity 
(Cronbach’s 
Alpha) 
 
Measure 
Internal 
Validity 
(Cronbach’s 
Alpha) 
Illness Perceptions 
Questionnaire Revised 
Identity 
Timeline 
Acute/Chronic 
Consequences 
Personal control 
Treatment Control 
Illness Coherence 
Timeline Cyclical 
Emotional Responses 
 
 
.84 
.56 
 
.79 
.78 
.51 
.87 
.90 
.91 
 
 
Celiac Disease 
Questionnaire-
Health Related 
Quality of Life 
Gastrointestinal 
Emotional 
Social 
Diagnosis and 
Treatment 
Worries 
 
 
 
.85 
.90 
.84 
 
.86 
 
 
Depression Anxiety 
Stress Scale 
Depression 
Anxiety 
Stress 
 
 
.93 
.86 
.91 
 
 
Brief COPE 
Problem focussed 
Emotion focussed 
Dysfunctional 
 
.81 
.68 
.73 
 
 
 
Illness Perceptions – IPQ-R 
Table 3 shows the means and standard errors for illness perception subscales. Most 
participants reported that 4 of the 20 symptoms listed in the Identity subscale were related to 
their CD. There was a belief that the consequences of CD were moderately severe. A strong 
sense of personal control was reported by this sample; with participants agreeing that their 
actions affected the outcome of their CD. A good understanding of the condition (illness 
coherence) is also evident. This sample disagreed that the symptoms of their CD were 
cyclical, or changeable and unpredictable from day to day, and equally disagreed that having 
CD caused negative emotional responses.  
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Table 3: Means and standard errors for illness perception subscales  
 
Identity Consequences 
Personal 
Control 
Illness 
Coherence 
Cyclical Emotional 
 N 1578 1578 1578 1578 1578 1578 
Mean 4.51 3.48 4.31 4.21 2.26 2.55 
Std. 
Error 
.10 .02 .02 .02 .03 .03 
Note: Scores for Identity range from 0-20, all other scores range from 1-5 
 
Overall, this sample reported they understood their CD and believed they could influence it 
through their actions. They felt their CD was generally predictable and they knew what to 
expect day to day. They had few negative emotional reactions to the condition, possibly 
because of the confidence they had in their own ability to manage it. 
To further explore these results bivariate correlations (Spearman’s Rho for non-parametric 
data) were completed for the IPQ-R subscales (Table 4). All results were significant at p<  
.01 apart from personal control and consequences (rs=-0.03, p<  .19), there is no significant 
link between believing your own actions influence the outcome of your CD and belief in the 
severity of the consequences of the condition. Although not significant, the direction of the 
correlation suggests that as personal control increased belief in the negative consequences of 
CD decreased.  
The strongest correlation (rs= -.78, p<  .01) was between personal control and identity and 
reflected the confidence this sample had in their ability to manage their CD through their own 
actions; the more people felt they themselves could affect their CD the fewer symptoms they 
reported as being related to the condition. 
There was a strong link between emotion and consequences (rs= .62, p<  .01), which means 
the more participants reported negative emotional reactions to their condition, the more they 
believed the consequences of having CD were serious. 
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Table 4: Spearman’s Rho correlations for IPQ-R subscales 
 Identity Consequences 
Personal 
Control 
Illness 
Coherence 
Cyclical 
Consequences .28**     
Personal Control -.78** -.03    
Illness Coherence -.16** -.23** .40**   
Cyclical .39** .27** -.27** -.45**  
Emotional .30** .62** -.23** -.43** .44** 
** Correlation is significant at p<  .01 
 
Wellbeing – DASS21 
Following recent precedent (Eisendrath, 2016; Henning et al., 2014) DASS21 total scores 
were used as a robust indication of general psychological wellbeing in this sample, lower 
scores indicated better outcomes. Mean score was M=9.24 (SE=0.123, possible range 0 to 
21), which indicated scores in the normal range 0-14.  
The results were also examined to identify if there were changes to psychological wellbeing 
in relation to gender and duration of diagnosis (Table 5; from original dataset). There was no 
significant correlation between duration of CD diagnosis and DASS21 total score for male 
participants (rs=-.011, p>.05), but female participants showed a small, but significant (rs=-
.157, p<  .01) negative correlation. This meant that over time DASS21 total scores were 
likely to fall, indicating that psychological wellbeing increases with time following CD 
diagnosis.  
Table 5: Spearman’s Rho correlation for DASS21 total and years since diagnosis by gender 
Male  Female 
 Years Since Diagnosis   Years Since Diagnosis 
DASS 21 
Total 
-.011  
DASS 
21 Total 
-.157** 
** Correlation is significant at p<  .01 
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Quality of Life – CDQ 
Lower mean scores indicate lower quality of life (Table 6). This sample was least concerned 
with the social implications of CD (M=5.72, SE= .03) and reported that they only altered or 
cancelled social plans ‘a little of the time’ as a result of CD. The sample also reported 
struggling with the gastrointestinal symptoms of the disease ‘a little of the time’ (M=5.34, 
SE= .03). This reflected previous findings that this is a sample who had well-managed CD 
and experienced few gastrointestinal symptoms.  
There was more concern regarding the diagnosis and treatment of CD (M=5.02, SE= .04) 
however, the emotional consequences of the condition had the greatest negative effect on 
quality of life (M=4.64, SE= .03). 
Table 6: Means and standard errors for the CDQ subscales  
 
Gastrointestinal Emotional Social 
Diagnosis and 
Treatment Worries 
 N 1578 1578 1578 1578 
Mean 5.34 4.64 5.72 5.02 
Std. Error 0.03 0.03 0.03 0.04 
Note: Scores range from 1-7 
 
Bivariate correlations (Spearman’s Rho) were completed for the subscales of the CDQ (Table 
7). All were significantly, positively correlated (p<  .01) showing that as quality of life in one 
area was affected, all other areas were also affected. The strongest correlation was between 
treatment and diagnosis worries and social effects (rs=0.70, p<  .01). The more individuals 
worried about the diagnosis and treatment of CD, and the burdens that this involved, the more 
they reported changed and cancelled social plans or felt unsupported by their social network.  
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Table 7: Spearman’s Rho correlations for CDQ subscales 
 Gastrointestinal Emotional Social 
Emotional 0.60**   
Social 0.56** 0.62**  
Diagnosis and 
Treatment Worries 
0.53** 0.55** 0.70** 
** Correlation is significant at p<  .01 
 
The CDQ asked participants to give their answers based on the past two weeks of their 
experience, rather than over a longer or undefined period of time such as the IPQ-R. To 
investigate the effect of duration of diagnosis on quality of life, CDQ subscales were 
compared to years since diagnosis (from original dataset) the results are shown in Table 8 
below.  
Table 8: Spearman’s Rho correlations for CDQ and years since diagnosis of CD 
 Years Since Diagnosis 
Gastrointestinal .026 
Social .024 
Emotional .059* 
Diagnosis and Treatment 
Worries 
.062* 
* Correlation is significant at p< .05 
 
 
As years since diagnosis increased, emotional and diagnosis and treatment worries around 
CD increased (rs= .059, p< .05 and rs= .062, p< .05 respectively), which had a positive 
impact on quality of life. These relationships were small, but significant at p< .05 in this 
sample. The reason for this may be that this sample was confident in their own ability to 
manage their CD well, however, when they were in social situations this was initially more 
difficult, but became easier as their experience and confidence increased with years since 
diagnosis. As years since diagnosis increase, individuals may experience less accidental 
exposure to gluten than they expected when not at home and could initially be more inclined 
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to cancel social plans to avoid accidental exposure until they realise this fear is unfounded. 
Worries about diagnosis and treatment may be time sensitive as participants have fewer 
worries about these issues as years since they were diagnosed increases. 
 
Coping – Brief COPE 
The Brief COPE measures coping styles across 14 subscales, which are frequently combined 
to the three used here. Higher scores indicated more coping strategies from this subscale were 
used (Table 9). 
 Table 9: Means and standard errors for the Brief COPE subscales  
 Problem 
Focussed 
Emotion 
Focussed 
Dysfunctional 
 N 1578 1578 1578 
Mean 1.930 1.949 1.381 
Std. Error .021 .016 .011 
 Note: Scores range from 1-4   
 
This sample most commonly used emotion focussed coping strategies of positive re-framing, 
using emotional support, humour, acceptance and religion to enable them to cope with their 
CD (M=1.949, SE=.016). They also used problem focussed coping strategies of using 
instrumental support, being active in the way they deal with issues and planning for problems 
before they occur (M=1.930, SE=.021). The final coping style is dysfunctional, this is the 
least used type of strategy and is made up of self-distraction, denial, substance use, 
behavioural disengagement, venting and self-blame (M=1.381, SE= .011).  
Inter-correlations between subscales were examined using Spearman’s Rho as the data 
violated the assumptions for parametric analysis (Table 10). 
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Table 10: Spearman’s Rho correlations for the Brief COPE subscales 
 Problem Focussed Emotion Focussed 
Emotion focussed .736**  
Dysfunctional .571** .478** 
** Correlation is significant at p< .01 
 
All subscales were positively correlated at p< .01. It might have been assumed that adaptive 
(problem focussed or emotion focussed) copers would not use dysfunctional coping 
strategies, however this result suggested that people who used a lot of strategies used 
adaptive and dysfunctional techniques rather than using strategies from one subscale only. 
There was some indication that adaptive copers used more adaptive strategies; the strongest 
correlation was between emotion and problem focussed strategies (rs= .736, p< .01) and the 
weakest correlation is between dysfunctional and emotion focussed coping (rs= .478, p< .01). 
 
Self-Efficacy – ASES 
Higher self-efficacy for the GFD was indicated by higher scores; range 0 to 10. The sample 
in this study were highly self-efficacious (M=8.398, SE= .039). There was no significant 
correlation between ASES total score and duration of diagnosis (rs= .022, p= .535). A Mann-
Whitney U test (non-parametric data) revealed there was no significant difference between 
males’ and females’ scores on the ASES. 
ASES correlated with all mediating and outcome variable subscales at significance p< .01 
and with the Brief COPE subscales (Table 11). 
 Table 11: Spearman’s Rho correlations for ASES, DASS, CDQ and Brief COPE subscales 
 DASS  CDQ Brief COPE 
 Total Gastro. Emo. Social 
D and T 
Worries 
Emotion Problem Dysfunc. 
ASES -.270** .259** .301** .317** .305** -.095** -.169** -.297** 
** Correlation is significant at p< .01 
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As self-efficacy increased, quality of life also increased across all subscales, the largest effect 
was for social impact. Conversely as self-efficacy increased DASS21 total reduced meaning 
psychological wellbeing improved. Interestingly self-efficacy was negatively correlated with 
the Brief COPE, which indicated that as self-efficacy increased the number of coping 
strategies reduced. This effect was largest for dysfunctional coping strategies and although 
very small, was also the case for problem and emotion focussed coping as well. 
 
Hypothesis Testing 
Hypothesis One:  
“There will be a relationship between illness perception and the outcomes (a & b) as 
illness perceptions become more negative outcomes will reduce 
a) psychological wellbeing  
b) quality of life” 
 
To test this hypothesis bivariate correlations were completed to identify the presence and 
direction of relationships between variables, correlation coefficients are shown in Table 12 
below. All correlations were significant at p= .01 and the direction of the relationships were 
as expected so the null hypothesis can be rejected; there is a relationship between illness 
perception, psychological wellbeing and quality of life.  
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Table 12: Spearman’s Rho correlations for illness perception, psychological wellbeing and 
quality of life subscales 
 
Psychological 
Wellbeing 
Quality of Life 
 DASS Total 
CDQ  
Gastrointestinal Emotional Social 
D and T 
Worries 
Identity .176** -.407** -.313** -.340** -.310** 
Consequences .226** -.342** -.422** -.544** -.511 
Personal 
Control 
-.132** .212** .210** .186** .162** 
Illness 
Coherence 
-.212** .299** .317** .314** .327** 
Cyclical .264** -.533** -.428** -.417** -.374** 
Emotional .410** -.419** -.583** -.587** -.564** 
** Correlation is significant at p< .01 
 
Hypothesis Two: 
 “There will be a relationship between illness perception and coping strategies. As 
illness perceptions become more negative more dysfunctional coping strategies will be 
used.” 
To test this hypothesis bivariate correlations were completed to identify the presence and 
direction of relationships between variables, correlation coefficients are shown in Table 13 
below. All correlations were significant at p< .001 apart from personal control and problem 
focussed coping (rs= .039, p= .25). An explanation for this may be that participants who have 
high personal control use a lot of problem focussed coping strategies, such as advanced 
planning. Alternatively, people with a strong sense of personal control may feel that they do 
not have to use many problem focussed strategies because they have confidence in their 
ability to deal with any issues at the time, should they arise.  Individuals with lower personal 
control may not be able to plan for problems before they occur and so would use fewer 
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problem focussed coping strategies or they may unsuccessfully or unnecessarily use a lot of 
problem focussed coping strategies because they feel their ability to personally control the 
outcome of their CD is poorer.  
Excluding personal control and problem focused coping, the null hypothesis can be rejected; 
there is a relationship between illness perceptions and coping strategies. However, the 
direction of these relationships does not match those made in the hypothesis. 
Table 13: Spearman’s Rho correlations for illness perception and coping subscales 
 Coping Strategies 
 Problem Focussed Emotion Focussed Dysfunctional 
Identity .184** .159** .231** 
Consequences .300** .233** .387** 
Personal Control .039 .089** -.162** 
Illness Coherence -.159** -.082** -.284** 
Cyclical .228** .159** .340** 
Emotional .309** .234** .547** 
** Correlation is significant at p< .01 
 
Hypothesis Three: 
“There will be a relationship between coping strategies and the outcomes (a & b). As 
more dysfunctional coping strategies are used outcomes will reduce” 
To test this hypothesis Spearman’s Rho correlations were completed to identify the presence 
and direction of relationships between variables (Table 14). All correlations were significant 
at p< .01, and the direction of the relationships were identified by the hypothesis so the null 
hypothesis can be rejected; there is a relationship between coping strategies, psychological 
wellbeing and quality of life and as more dysfunctional coping strategies are used outcomes 
will reduce. 
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Table 14: Spearman’s Rho correlations for coping, psychological wellbeing and quality of 
life subscales 
 
Psychological 
Wellbeing 
Quality of Life (CDQ) 
 DASS Total Gastro. Emotional Social 
D + T 
Worries 
Problem 
Focussed 
.292** -.257** -.308** -.337* -.363** 
Emotion 
Focussed 
.239** -.185** -.198** -.238** -.250** 
Dysfunctional .507** -.407** -.603** -.523** -.483** 
** Correlation is significant at p< .01 
 
The PROCESS algorithm by Hayes (2013) has become a popular resource for the analysis of 
moderation and mediation models. Unfortunately, the PROCESS algorithm is not appropriate 
for use with multiple imputation (MI) data as it requires bootstrap estimates of standard error 
of the indirect effects within the model and there is currently no consensus on how to apply 
the bootstrap across MI data. As an alternative, the LAVAAN (Rosseel, 2012) package in R 
Studio calculates structural equation models (SEM) with missing data accommodated using 
full information maximum likelihood (FIML) estimators. FIML is found to be at least as 
robust as MI (Peyre et al., 2010) and produces comparable results (Collins et al., 2001) in fact 
FIML produces slightly smaller standard errors than MI (Dong & Peng, 2013). 
To test the final two hypotheses, therefore, a project-specific program was written by Dr 
Christopher Jones (University of Birmingham) to allow a FIML version of Hayes (2013) 
moderated mediation model (Hayes, 2013) model 7 to be analysed using the LAVAAN 
package within R Studio. 
 
 
 85 
 
Hypothesis Four: 
“The relationship between illness perceptions and the outcomes (a & b) will be mediated 
by coping strategies” 
Conceptual and statistical illustrations shown below (Figure 2.1 & 2.2). Mediated pathways 
were shown by significant route estimates for both routes x~m and m~y for each variable. In 
this model, there were multiple variables in x, m and y; with the exception of the mediator 
variables each variable was analysed separately. The direction of the relationship was 
indicated by positive or negative route estimates. 
 
Figure 2.1: Conceptual illustration of a mediated model with multiple mediators  
(taken from Hayes, 2013) 
 
 
Figure 2.2: Statistical illustration of a mediated model with multiple mediators  
(taken from Hayes, 2013) 
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Tables 15 to 18 show significant route estimates, standard error and alpha levels from illness 
perceptions to psychological wellbeing and quality of life mediated by coping strategy. For 
illustrations of significant pathways see Appendix C.   
Table 15: Significant routes from x~m for DASS 
Route x~m 
(outcome DASS) 
m=Brief COPE 
Emotion Focussed (m1) Dysfunctional (m3) 
Est. SE p Est. SE p 
x
=
IP
Q
R
 Emotion 0.192 .025 < .001 0.378 .018 < .001 
Coherence -0.090 .042 < .001 -.0283 .033 < .001 
Consequences 0.255 .033 < .001 0.303 .025 < .001 
Personal Control - - - -0.138 .030 < .001 
Cyclical 0.194 .040 < .001 0.350 .031 < .001 
 
 
Mediation occurred across all included variables in the IPQR apart from personal control and 
emotion focussed coping. There were no mediated pathways between the IPQR and problem 
focussed coping. The null hypothesis can be partially rejected as the majority of the 
relationships between illness perceptions and psychological wellbeing were mediated by 
coping.   
 
Table 16: Significant routes from m~y for DASS 
Route m~y 
y=DASS 
Total 
Est. SE P 
m
=
B
ri
ef
 C
O
P
E
 
m
1
 
Emotion -.055 .022 .011 
Coherence -.047 .022 .035 
Consequences -.058 .022 .008 
Personal Control - - - 
Cyclical -.049 .022 .026 
m
3
 
m
3
 
   
 
Emotion .483 .024 < .001 
Coherence .567 .023 < .001 
Consequences .550 .023 < .001 
Personal Control .569 .022 < .001 
Cyclical .553 .023 < .001 
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“ – “ No significant route 
 
Table 17: Significant routes from x~m for CDQ 
Route x~m 
m=Brief COPE 
Emotion Focussed (m1) Problem Focussed (m2) Dysfunctional (m3) 
Outcome CDQ Gastro Est. SE p Est. SE P Est. SE p 
x
=
IP
Q
R
 Emotion - - - - - - .378 .018 < .001 
Coherence - - - - - - -.282 .033 < .001 
Consequences - - - - - - .303 .025 < .001 
Personal Control - - - .088 .030 .003 -.135 .030 < .001 
Cyclical - - - - - - .356 .031 < .001 
Outcome CDQ Emotion 
x
=
IP
Q
R
 Emotion .191 .025 < .001 - - - .375 .018 < .001 
Coherence -.088 .042 .035 - - - -.276 .033 < .001 
Consequences .255 .033 < .001 - - - .303 .025 < .001 
Personal Control .169 .038 < .001 .089 .030 .003 -.130 .029 < .001 
Cyclical .192 .040 < .001 - - - .353 .031 < .001 
Outcome CDQ Social 
x
=
IP
Q
R
 Emotion .192 .025 < .001 .172 .020 < .001 .378 .018 < .001 
Coherence - - - -.140 .033 < .001 -.287 .033 < .001 
Consequences .256 .033 < .001 - - - .302 .025 < .001 
Personal Control - - - .088 .030 .003 -.141 .002 < .001 
Cyclical - - - .203 .031 < .001 .353 .031 < .001 
Outcome CDQ Diagnosis and Treatment 
x
=
IP
Q
R
 Emotion - - - .174 .020 < .001 .377 .018 < .001 
Coherence - - - -.141 .033 < .001 -.286 .033 < .001 
Consequences .259 .033 < .001 .224 .025 < .001 .298 .025 < .001 
Personal Control - - - .086 .029 .003 -.142 .030 < .001 
Cyclical - - - .203 .031 < .001 .349 .031 < .001 
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         Table 18: Significant routes from m~y for CDQ 
 y=CDQ 
Route m~y Gastrointestinal Emotional Social 
Diagnosis + 
Treatment 
 Est. SE p Est. SE p Est. SE p Est. SE p 
m
=
B
ri
ef
 C
O
P
E
 
m
1
 
Emotion - - - .129 .040 .001 .107 .041 .009 - - - 
Coherence - - - .086 .042 .041 - - - - - - 
Consequences - - - .136 .041 .001 .131 .042 .002 .126 .052 .015 
Personal Control - - - .094 .043 .029 - - - - - - 
Cyclical - - - .105 .041 .011 - - - - - - 
m
2
 
Emotion - - - - - - -.155 .055 .005 -.355 .066 < .001 
Coherence - - - - - - -.121 .060 .042 -.342 .072 < .001 
Consequences - - - - - - - - - -.311 .068 < .001 
Personal Control -.123 .057 .031 -.113 .057 .046 -.181 .060 .003 -.406 .073 < .001 
Cyclical - - - - - - -.122 .058 .036 -.340 .071 < .001 
m
3
 
Emotion -.369 .047 < .001 -.699 .043 < .001 -.418 .045 < .001 -.364 .055 < .001 
Coherence -.503 .043 < .001 -.942 .042 < .001 -.696 .045 < .001 -.669 .054 < .001 
Consequences -.491 .043 < .001 -.909 .041 < .001 -.612 .042 < .001 -.589 .052 < .001 
Personal Control -.528 .043 < .001 -.979 .042 < .001 -.739 .045 < .001 -.719 .055 < .001 
Cyclical -.381 .039 < .001 -.899 .041 < .001 -.665 .044 < .001 -.649 .054 < .001 
 “ - “ No significant route 
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Mediation occurred via dysfunctional coping across all predictor variables at p< .001. 
Personal control was also mediated by problem focussed coping across all outcomes of the 
CDQ. Emotion focussed coping mediated the CDQ emotion pathway across all subscales of 
the IPQR. Problem focussed coping mediated all routes from the IPQR variables for CDQ 
social and CDQ diagnosis and treatment (apart from the IPQR consequences subscale, which 
had no significant mediation from problem focussed coping). The final significant mediation 
effects were from the IPQR consequences subscale via emotion focussed coping for CDQ 
social and CDQ diagnosis and treatment where both x~m and m~y p≤ .01 and IPQR emotion 
subscale to CDQ social via emotion focussed coping (x~m p< .001, m~y p= .009). Again, the 
null hypothesis can be partially rejected as the majority of the relationships between illness 
perceptions and quality of life were mediated by coping.   
 
Hypothesis Five: 
“Dietary self-efficacy will moderate the mediation of coping strategies on the 
relationships between illness perceptions and the outcomes (a & b)” 
A conceptual illustration of this model is shown in Figure 3.1 and 3.2 below. For illustrations 
of significant routes and amount of variance explained by the model see Appendix D. 
This model examined whether different levels of the moderator acted on the mediator to 
change the indirect relationship between the predictor (x) and dependant (y) variables. In this 
model, the moderator (ASES) was centred and three levels; 1 standard deviation (SD) above, 
at and below the mean were used to identify the direction of any moderated mediation effects 
(Tables 19 and 20). 
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Figure 3.1: Conceptual illustration of a moderated mediated model with multiple mediators  
(taken from Hayes, 2013) 
 
 
Figure 3.2: Statistical illustration of a moderated mediated model with multiple mediators  
(taken from Hayes, 2013) 
 
 
 
Moderated mediation further explained all the significant routes found using the mediation 
model for the outcome of DASS total, apart from IPQR emotion and Brief COPE 
dysfunctional coping and IPQR personal control and Brief COPE dysfunctional coping. In 
these cases, mediated routes were found, but they were not moderated by self-efficacy. All 
other routes were moderated by self-efficacy and 71% (n=5) of these showed that as self-
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efficacy went up the model became more significant. For the other 2 routes p< .001 and a 
direction could not be identified as a result of the sensitivity of the test being reached. 
Tables 19 and 20 showed that there were a number of wx~m routes that were mediated by 
coping, but were not moderated by self-efficacy (highlighted). All of these fell into the 
dysfunctional coping subscale and are IPQR emotion or IPQR personal control routes.  
All other mediated routes previously identified were further explained by including the 
moderating effects of self-efficacy; 52% (n=17) of the significant routes showed moderation 
was more significant as self-efficacy scores increased, a further 9 (27%) were significant at 
p< .001 at all levels of the moderator, 15% (n=5) increased in significance as self-efficacy 
reduced and 2 (6%) do not reach significance (p< .05) at any level. 
For all outcomes, the null hypothesis can be partially rejected as the majority of the mediated 
relationships between illness perceptions, psychological wellbeing and quality of life were 
moderated by self-efficacy.   
Table 19: Significant routes from wx~m for DASS 
Route wx~m 
(outcome  
DASS) 
m=Brief COPE 
Emotion 
Focussed (m1) 
w 
Dysfunctional 
(m3) 
W 
Est. SE p ASES Est. SE p ASES 
x
=
IP
Q
R
 Emotion .005 .001 < .001 ↑ - - - - 
Coherence -.005 .001 < .001 ↑ -.003 .001 < .001 ↑ 
Consequences .005 .001 < .001 ↑ .002 .001 .014 All 
Personal Control - - - - - - - - 
Cyclical .004 .001 .001 ↑ .002 .001 .001 All 
Note: Arrows indicate significance at 1 SD above (↑), at (--) or below (↓) M, “All” indicates significance of p< 
.001 at all levels of moderator 0 indicates no level achieves significance at p< .05 
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Table 20: Significant routes from wx~m for CDQ 
Route wx~m 
m=Brief COPE 
Emotion Focussed (m1) w Problem Focussed (m2) w Dysfunctional (m3) w 
CDQ Gastro Est. SE p ASES Est. SE P ASES Est. SE p ASES 
x
=
IP
Q
R
 Emotion - - - - - - - - .001 .000 .04 All 
Coherence - - - - - - - - -.003 .001 < .001 ↑ 
Consequences - - - - - - - - .002 .001 .005 All 
Personal Control - - - - -.002 .001 < .001 ↑ - - - - 
Cyclical - - - - - - - - .002 .001 < .001 All 
CDQ Emotion 
x
=
IP
Q
R
 Emotional .005 .001 < .001 0 - - - - - - - - 
Coherence -.005 .001 < .001 ↓ - - - - -.003 .001 < .001 ↑ 
Consequences .005 .001 < .001 ↑ - - - - .002 .001 .007 All 
Personal Control -.003 .001 < .001 ↓ -.002 .001 < .001 0 - - - - 
Cyclical .004 .001 < .001 ↑ - - - - .002 .001 < .001 All 
CDQ Social 
x
=
IP
Q
R
 Emotional .005 .001 < .001 ↓ .003 .000 < .001 ↑ - - - - 
Coherence - - - - -.004 .001 < .001 ↑ -.003 .001 < .001 ↑ 
Consequences .005 .001 < .001 ↑ - - - - .002 .001 .010 All 
Personal Control - - - - -.002 .001 < .001 ↓ -.001 .001 .049 ↑ 
Cyclical - - - - .003 .001 < .001 ↑ .002 .001 < .001 All 
CDQ Diagnosis and Treatment 
x
=
IP
Q
R
 Emotion - - - - .003 .000 < .001 ↑ - - - - 
Coherence - - - - -.004 .001 < .001 ↑ -.003 .001 < .001 ↑ 
Consequences .005 .001 < .001 ↑ .004 .001 < .001 ↑ .002 .001 .007 All 
Personal Control - - - - -.002 .001 < .001 ↓ - - - - 
Cyclical - - - - .003 .001 < .001 ↑ .002 .001 < .001 All 
       “ – “ No significant route
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DISCUSSION 
To the author’s knowledge this is the first study that has examined moderated mediation 
effects of dietary self-efficacy and coping style on illness perceptions and the outcomes of 
psychological wellbeing and quality of life. It is certainly the first study to use the LAVAAN 
package and FIML missing data handling to analyse Hayes (2013) model 7 with multiple 
mediators.   
The results of this study concur with those of Gonzalez et al. (2015); participants with more 
perceived control report better psychological wellbeing and better quality of life.  Personal 
control is negatively correlated with dysfunctional coping. Individuals who feel more in 
control manage their illness better and use fewer dysfunctional coping strategies (Ford et al., 
2012).  
This study challenges the findings of others who have reported reduced psychological 
wellbeing over time (Brands et al., 2004) and that adults with CD experience anxiety 
(Baiardini et al., 2012), but supports those who have found depression reduces as time post-
diagnosis increases (Van Hees et al., 2013). This sample experienced levels of psychological 
distress similar to that of the general population. No significant impact of duration of 
diagnosis was found for male participants and female participants showed an increase in 
wellbeing with years since diagnosis. Bearing in mind that this is a highly self-efficacious 
sample, this increase in wellbeing may be evidence of the feedback loop Karademas et al. 
(2011) described.  
As has been suggested previously (Barratt et al., 2011) poorer psychological wellbeing was 
correlated with dysfunctional coping as well as less perceived personal control and a more 
negative emotional impact of CD. 
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The results were more congruous with American and Canadian studies identified by Hauser 
et al. (2007) as quality of life was high. This may be due to the sampling method used: People 
who are involved with Coeliac UK and who have the time and inclination to take part in a 
survey such as this may be less likely to be those who feel overwhelmed by their condition. 
Previous studies have reported individuals with well-managed CD are less likely to use 
emotional regulation or distraction as coping strategies (Wagner et al., 2016) and those who 
are self-compassionate have better quality of life (Dowd & Jung, 2017). These finding are 
suggested here; self-compassion most closely resembles the activities identified in the 
emotional coping subscale of the Brief COPE (Neff, 2003 & 2009) and this subscale has the 
smallest correlation with dysfunctional coping suggesting that to a small degree people who 
use dysfunctional coping strategies are less likely to use emotion focussed ones.  
There are negative correlations between all coping strategies and all quality of life subscales. 
The same is true for self-efficacy and coping strategies. For both quality of life and self-
efficacy this effect is largest for dysfunctional coping strategies. An explanation for this may 
be that as self-efficacy and quality of life increase coping strategies are no longer seen as 
‘strategies’ and so are not reported in the same way. 
High self-efficacy alone is not enough to account for positive health outcomes (Schwarzer & 
Renner, 2000); the complex results of the moderated mediation of self-efficacy found in this 
study would certainly support this. McDonald (2002) warns against assigning causality to the 
results of SEM. This study, however, formulates the effects of self-efficacy prior to coping 
strategies and the number of significant routes identified shows that, for these variables at 
least, the direction is correct.  
For psychological wellbeing, the indirect relationship between all illness perceptions and 
psychological wellbeing is moderated by level of self-efficacy via emotion focussed coping 
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and dysfunctional coping, but not problem focussed coping. This may appear surprising as 
Jex et al. (2001) found that active coping (contained within the problem focussed subscale) 
and self-efficacy mediated stressor-strain relations. However, Knowles et al. (2014) report 
comparable results; emotion and dysfunctional coping mediated anxiety and depression in 
adults with stoma. They also found self-efficacy reduces depression, but not anxiety. The 
cause of difficulty may also be relevant here. Byrd O'Brien & De Longis (1996) looked at 
interpersonal and agentic stressors on a small sample of adolescents with anxiety and found 
that different types of coping were used depending on where the stressor originated; for 
agentic (situational) stressors, problem-focussed strategies were more likely to be used. If 
participants did not consider their CD or the management of it to be situational, but rather felt 
that the issues were interpersonal – which is suggested by the higher mean score on the social 
impact on quality of life – it follows that problem focussed coping would not be mediated or 
moderated in this study. 
There is no moderated mediation effect of personal control and psychological wellbeing 
through any coping style and emotion and psychological wellbeing is only moderated via 
emotion focussed coping. Perceived personal control and emotional impact were not 
originally included in the IPQR and were added to the measure later (Moss-Morris et al., 
2002); if the theory behind the constructs differs slightly from the original scale, this may be 
why they produce different results. 
For quality of life, moderated mediation occurs via dysfunctional coping across all IPQR 
variables at p< .001 other than personal control x dysfunctional coping for any CDQ outcome 
or for IPQR emotion x dysfunctional coping for CDQ emotion or diagnosis and treatment 
outcomes. Level of self-efficacy appears to have a particular role within dysfunctional 
coping. Thomasson & Psouni (2010) report that low self-efficacy is linked with the use of 
dysfunctional coping strategies and in turn this type of coping leads to increased negative 
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emotional responses and reduced quality of life. Norcini Pala & Steca (2015) also found 
dysfunctional coping played a significant role in the relationship between illness perception 
and disease outcomes in HIV positive adults.  
Personal control is mediated by problem focussed coping and moderated by self-efficacy 
across all outcomes of the CDQ. This relationship generally increases in significance as self-
efficacy reduces, which means the lower an individual’s self-efficacy is, the more likely they 
are to use problem-focussed coping strategies to help manage their CD and improve their 
quality of life. Diehl & Hay (2010) demonstrate that levels of perceived personal control 
fluctuate depending on daily stresses. In the current study stresses may relate directly to CD 
and its management as this was the focus of measures and questioning. This corresponds with 
Bandura (1994) and Karademis et al’s (2001) idea that examples of positive coping lead to 
higher confidence and higher self-efficacy to continue to deal with the problem in the future. 
Emotion focussed coping moderates all subscales of the IPQR via the CDQ emotion pathway. 
For the illness perceptions of coherence and personal control the relationship gets more 
significant as self-efficacy decreases. For consequences and cyclical subscales, the opposite 
is true. In this sample, believing there are serious negative consequences of CD and that CD 
is cyclical and unpredictable in nature leads to use of more emotion focussed coping 
strategies the more self-efficacious participants are. 
Similarly, problem focussed coping mediates all routes from the IPQR variables for CDQ 
social (apart from the IPQR consequences subscale) and CDQ diagnosis and treatment. The 
indirect relationship from personal control becomes more significant as self-efficacy 
decreases for all other significant variables the opposite is true and routes increase in 
significance as self-efficacy improves.   
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The final significant moderated mediation effects are from the IPQR consequences subscale 
via emotion focussed coping for CDQ social and CDQ diagnosis and treatment. Both increase 
in significance as self-efficacy increases. This suggests that having higher self-efficacy for a 
GFD will make it more likely an individual will use emotional coping strategies if they feel 
their quality of life is affected by the social and diagnosis and treatment process of CD. 
  
Limitations, Strengths and Future Research 
There were a number of limitations to this study. The time frame for the different measures 
used varies from the last 2 weeks to no end date. This makes it difficult to directly compare 
the results across variables. This was handled during the analysis by looking at correlations 
between duration of diagnosis and various variables, but this is perhaps not the most reliable 
method. Future research may be able to more fully address this issue. 
Although widely used in research, Moss-Morris et al. (2002) do not recommend condensing 
the 14 subscales of the Brief COPE, in doing so the nuances of relationships between the 
different aspects of the problem focused coping subscale may be lost. Unfortunately, to do 
this would have been beyond the capabilities of this study.  
McDonald (2002) warns about the issues of establishing causality from the results of SEMs 
and with the design of this study being new in its field such warnings should be given greater 
consideration to avoid accepting spurious results. However, at each stage of the design and 
analysis of this study, up to date literature as to the most robust and reliable methods were 
consulted and considered to avoid error as far as possible. 
As a sample, participants were highly self-efficacious when it came to their GFD. It might 
have been useful to include a more general measure of self-efficacy alongside the ASES 
used. However, as this study was looking directly as CD-related self-efficacy, illness 
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perceptions and outcomes, this measure was appropriate. Another test of dietary self-
management such as that developed by Leffler et al. (2009) could have been useful to provide 
a less subjective measure. Although the 6-item questionnaire used here had excellent internal 
validity (.96) it was not able to assess detail. 
Recruitment of the sample through the Coeliac UK website may have caused some sampling 
bias. The individuals that use the website may be more self-efficacious and motivated than 
the general CD population as they are actively seeking help and support for their condition. 
The breakdown of educational level also suggests this sample may not be typical of the 
general population it represents as 50% of participants were educated to at least university 
level. 
The data used in this research was gathered in 2009-2010; therefore, it is possible that the 
increased recognition of CD by the public and catering establishments (Aziz et al., 2014), and 
greater availability of gluten-free foods in supermarkets may influence findings if this study 
were to be repeated today. However, despite the increased  availability of gluten free foods 
for consumption at home and when out (Burden et al., 2015), these options remain expensive. 
The participants in this sample were already very good at following a GFD and were highly 
self-efficacious, so this change may have had less of an impact on this sample than others 
who were finding dietary management more difficult or who were from lower socio-
economic backgrounds.  
As a comment on the process of producing this research, using data collected and coded by a 
previous research team made initial data cleaning difficult and time consuming. It was 
necessary to deal with possible coding mistakes or unknown coding strategies as missing 
data, which increased the importance of strong and reliable methods to deal with missing data 
throughout analysis. 
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The study here included a large number of variables and as a result the results are complex. In 
future particular aspects of the findings could be explored in more detail to add further detail 
to the field of psychological and quality of life outcomes for adults with CD. Of particular 
interest may be the lack of any indirect effect of problem-focussed coping for any illness 
perception for the outcome of psychological wellbeing. This is an interesting result as it 
might have been expected that coping strategies such as being active and planning played a 
large part in effectively managing a chronic condition such as CD. Further investigation 
would show whether this finding is specific to this sample or more general. 
Research using a longitudinal design would be informative as changes over time could be 
examined directly. The participants included here were asked to consent to future research as 
part of the survey and repeating this study design with current data would be a fascinating 
project.  
 
Model Testing 
The final limitation is also a strength; this was a model-driven study including a new 
procedure for handling missing data using FIML analysis with multiple mediators in a 
moderated mediation model based on Hayes (2013) model 7. This makes it harder to compare 
to the existing literature, but outlines an exciting new possibility for researchers wishing to 
look at more complex moderated mediation effects with a robust treatment of missing data. In 
addition to the hypotheses outlined above this study was also testing the model. The presence 
of multiple, significant, moderated mediation pathways suggests that this was a valid model 
to apply to this type of investigation, as does the amount of variance explained by the model 
for each moderated mediation. 
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More use of this FIML moderated mediation model with multiple mediators will provide 
further information as to the strengths and weaknesses of this approach and allow 
development of statistical requirements such as minimum sample size to be established. The 
model elegantly negates the confusion associated with bootstrapping multiple imputation 
data. 
 
Clinical Implications 
Clinical Services 
The findings of this study suggest that improving self-efficacy for the GFD rather than 
focussing on nutritional or medical outcomes for self-management could be beneficial. The 
way this is done is also important; Gist et al. (2001) found that modelling new skills 
improved self-efficacy in participants who rated themselves as low in self-efficacy for a task. 
Modelling GFD choices may be more effective than giving people lists of gluten free food 
(Barlow et al., 2002). 
Assessing for and, where necessary, teaching more adaptive coping strategies is likely to 
improve outcomes in adults with CD in the same way as Wager et al. (2016) suggested it 
would be beneficial for adolescents with CD. Elfstrom et al. (2005) similarly concluded that 
rehabilitation needed to include teaching acceptance and facilitative coping strategies as well 
as the usual physical and practical dimensions. 
Developing treatment/support pathways across the lifespan would ensure individuals have 
access to the right support when it is needed. One in four adults with CD reported being 
dissatisfied with the information given to them by their consultant regarding a GFD (Ukkola 
et al., 2012) despite it being shown that understanding CD and a GFD improves adherence 
(Ludvigsson et al., 2015).  The clinical pathway could include initial assessment of all newly 
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diagnosed patients with CD and provide access to additional interventions as and when 
needed. 
Making use of the feedback loop of self-efficacy; support for newly diagnosed individuals 
could include identifying when they have exhibited good dietary self-efficacy. However, as 
self-efficacy reduces the use of dysfunctional coping strategies most, support in developing 
adaptive opposed to dysfunctional coping strategies also needs to occur. 
Psychological practitioners would ideally be involved in the care of individuals diagnosed 
with CD, particularly if assessment concluded that they have poor self-efficacy for the GFD, 
or are likely to use dysfunctional coping strategies. Policy makers would need to be aware of 
this in the design of new CD services. 
 
Service Users 
Unfortunately, these provisions do not currently exist for service users to make use of. 
Individuals with CD would have to seek out this support. Support groups may be the most 
realistic way to access modelling of a GFD, an opportunity to learn adaptive coping strategies 
and to build self-efficacy.  
While social support is certainly important for people with CD (Olsson et al., 2008), more 
structured groups may be more helpful for service users who need support with the GFD, 
developing coping strategies and improving self-efficacy. 
 
Policy makers 
Helping adults with CD develop skills around adaptive coping strategies and self-efficacy for 
a GFD may improve outcomes and may reduce the financial and time burdens on health 
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services. Better adherence to a GFD can reduce the need to treat conditions related to 
malabsorption. Other conditions such as low mood and anxiety may also reduce as people 
feel more confident in their ability to manage their condition, leading to less anxiety about 
accidental gluten ingestion and lower rates of depression as individuals will be more 
confident in their own self-efficacy, which as a result will improve further. Anxiety may 
further reduce if individuals know additional support is available should they need it. 
Conditions related to dysfunctional coping such as problematic alcohol use or substance 
misuse may also reduce as a result of modelling more adaptive coping strategies to 
individuals who are at risk of using dysfunctional ones. 
Although CD is primarily thought of as a medical condition, a more holistic approach is 
likely to have medical benefits as well as others such as improved quality of life and 
psychological wellbeing. An approach similar to the DESMOND (Diabetes Education and 
Self-Management for Ongoing and Newly Diagnosed) program for type 2 diabetes, would be 
a structured program that included educational and self-management aspects delivered by 
trained professionals and more flexible support and education groups (Skinner et al., 2006). 
Individuals that go through the program can also become trainers for newly diagnosed 
individuals and ‘experts by experience’. This holistic approach will enable more people to 
live happy, healthy and well with CD. 
 
CONCLUSION 
A number of complex indirect moderated mediated relationships were identified in relation to 
illness perceptions, the outcomes of psychological wellbeing and quality of life and the roles 
of self-efficacy and coping style. Higher self-efficacy for the GFD leads to a reduction in the 
use of coping strategies, with the largest effect on dysfunctional coping strategies.  
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Assessing self-efficacy following diagnosis of coeliac disease could be helpful in identifying 
individuals who may struggle to manage their condition and who therefore might not achieve 
good outcomes. The use of targeted support to follow a GFD with an emphasis on 
encouraging a sense of personal control is most likely to improve self-efficacy.  
Alongside this, supporting development of more adaptive coping strategies will further 
improve outcomes. The nature of this support is important, with modelling being the most 
effective way to enable individuals to learn and make use of new skills.  
Psychological wellbeing and quality of life have been consistently found to be more 
influential on individuals’ levels of disease-related distress than the number or severity of 
symptoms experienced. For the best outcomes, these factors need to be considered and 
treated as part of diagnosis and/or aftercare. 
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PUBLIC DISSEMINATION DOCUMENT 
This document summarises the systematic review and empirical study included in the thesis 
submitted by Josephine Talbot to the University of Birmingham for the degree of Doctorate 
of Clinical Psychology. 
 
Systematic review: 
What is the Evidence for Neurological and Cognitive Symptoms Associated 
with Coeliac Disease and Non-Coeliac Gluten Sensitivity in Adults? 
 
Introduction 
Coeliac disease (CD) is an autoimmune condition that effects around 1% of the UK 
population. It is triggered when gluten (which is a protein found in wheat) is eaten by 
someone who is genetically vulnerable to the condition. In the past it was thought to include 
only gastro-intestinal symptoms such as stomach pain, bloating and diarrhoea. More recently 
however, other symptoms have been linked with CD that do not involve gastro-intestinal 
symptoms at all. People with CD have reported fatigue, forgetfulness and feeling confused. 
So far there has been little research done to identify exactly what these symptoms are and 
how common they might be.  
Non-coeliac gluten sensitivity (NCGS) is a condition that has very similar symptoms to CD, 
however, whereas in CD there will be damage to the intestines that can be seen by biopsy, 
with NCGS the intestines remain healthy. The only treatment for both conditions is a life-
long gluten free diet (GFD). NCGS has suffered from being under-investigated and very little 
is known about the non-gastro-intestinal symptoms of this condition.  
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The aim of this review was to gather information from multiple sources to identify what is 
known about the non-gastro-intestinal symptoms of CD and NCGS. Within this the review 
separated symptoms into those that involved the nervous system (or neurological) and those 
that involved different type of thinking (or cognitive).  
 
Method 
Six online databases were searched and 114 articles were found, a set of inclusion criteria 
were applied to each of these articles, and those that met the criteria were included in the 
review. The final number was 21. Each article was then assessed to make a judgement on its 
quality. It is important to identify any issues with the quality of a study because poorly 
designed research may lead to incorrect results. 
 
Results 
More was written about the symptoms of CD than NCGS, however there was little difference 
between the 2 conditions in terms of the symptoms reported. There was also a difference 
between the amount and the quality of research done on the neurological symptoms and the 
amount and quality of research done on the cognitive symptoms. The neurological symptoms 
of slowed nerve conduction, pain and unusual sensations in hands and feet (e.g. pins and 
needles) were reported in a lot of studies and the studies were of high quality. For the 
cognitive symptoms there was far less agreement, with some studies even disagreeing about 
whether there are any cognitive symptoms at all. The review did find evidence for short-term 
memory problems and fatigue, but these conclusions cannot be made with much confidence 
as a result of the disagreement between studies. 
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Discussion 
Further research is needed to really clarify what, if any, cognitive symptoms are found in 
adults with CD and NCGS. There was agreement that both types of symptom improve or stop 
entirely when an individual follows a GFD. There was evidence that, for neurological 
symptoms, the level of improvement is linked to the severity of symptoms and the most 
unwell individuals are less likely to make a full recovery even on a GFD. This shows the 
importance of early diagnosis and treatment. 
 
EMPIRICAL PAPER: 
Adult Coeliac Disease (CD): Illness Perceptions, Psychological Wellbeing, 
Quality of Life and the Moderating and Mediating Roles of Coping and Self-
Efficacy 
 
Introduction 
There are lots of factors that affect how well someone manages a long-term illness such as 
CD. Previous research has shown that one of the most important is the way an individual 
understands their condition, for example whether they feel they have any control over the 
outcome, whether they think the treatment will work and whether they feel it is a serious 
long-term condition. One way to measure how well someone is coping is to look at the 
medical progress they are making, however in psychological research it is more useful to 
look at how well people are doing in terms of their mental health or psychological wellbeing. 
Another area of interest is quality of life, this looks at different areas and assesses overall 
how well someone is living, there are specific measures that look at quality of life in relation 
to an illness, so any negative impact of this can be measured. 
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The way people cope with CD can have a significant impact on their psychological wellbeing 
and quality of life. An example might be that someone who denies there is a problem with 
their health or who uses alcohol so that they don’t have to think about their illness is less 
likely to follow the proper diet, they are more likely to experience symptoms that affect their 
quality of life and this can also have a negative effect on their psychological wellbeing.  
The final factor this research looked at was self-efficacy, this is the belief that you have the 
ability to achieve a goal that you set yourself. In this research self-efficacy for a GFD was 
measured. People who have high self-efficacy are confident that they can reach a particular 
goal. People with low self-efficacy are less likely to try and reach their goal. 
All these factors are linked in the management of long-term conditions and the aim of this 
research was to take all of these factors into account and to explore whether level of self-
efficacy and coping style could predict the psychological wellbeing and quality of life in 
adults with CD. 
 
Method 
Information was gathered through an online questionnaire that was advertised on the Coeliac 
UK website (the leading charity for people with CD in the UK). This information was then 
analysed using a program written specifically for this study. It was able to take all the above 
factors into account in order to show whether the predicted relationships did in fact exist. 
 
Results  
The results of examining these relationships were complex, however, the research identified a 
number of important relationships. Overall, a person with higher self-efficacy is more likely 
to use fewer negative coping strategies, such as using alcohol or denying they have CD. 
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However, they will also reduce the number of positive coping strategies they use, like 
planning for problems and getting emotional support from other people when needed, but 
don’t reduce the use of these strategies as much as the negative ones. The results showed that 
using positive or negative coping strategies predicts someone’s psychological wellbeing, 
whereas only the use of negative coping strategies was able to predict quality of life. 
 
Discussion 
There is much that can be done to help adults with CD improve their wellbeing and quality of 
life, and this does not need to focus solely on better knowledge of the GFD. Teaching 
positive coping strategies is important so that people have lots of positive coping options to 
use even if they start to use fewer of them as their self-efficacy increases. Finally, supporting 
someone to build on their sense of self-efficacy is likely to be helpful because their 
confidence in following the diet should grow, their ability to follow the diet should grow and 
their symptoms should reduce improving their psychological wellbeing and quality of life.  
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APPENDICES FOR SYSTEMATIC REVIEW 
 
Appendix A - Reason articles rejected 
 
 
Participants are children = 57 
 
Mental health outcomes not neurological or cognitive = 20 
 
Participants are older adults = 8 
 
Participants do not have CD or NCGS = 1 
 
Not reporting original data = 2 
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Appendix B - Full text articles not available 
 
• Tirotta, Eusebi & Durante (2012) Celiac disease with epilepsy and minor neurological 
disorders. Recenti progressi in medicina, 103 (5), 198-204  
Requested via interlibrary loans: English translation not available 
• Peters, Yelland, Moore, Ward, Majumdar, Muir & Gibson (2016) No effect of gluten 
on anxiety or depression in patients with NCGS, but could it be brain fog? Journal of 
Gastroenterology and Hepatology, 150 (4)  
Requested via interlibrary loans: Abstract only available – full article not published 
• Longarini, Richly, De la Paz Temprano, Costa, Vazquez, Moreno, Niveloni, Lopez, Jer, 
Smecuol, Sugai, Mazure, Gonzelez, Maurino & Bai (2016) Cognitive performance in 
patients with celiac disease prevalence of cognitive impairment at diagnosis and effect 
of treatment assessed in a prospective controlled study. Gastroenterology, 150 (4) 
Requested via interlibrary loans: Summary only available 
• Duggan (1997) Recent developments in our understanding of adult coeliac disease. 
The Medical Journal of Australia, 166 (6), 312-315 
Author contacted via email – no response 
• Iani, Giorgetti, Loberti, Palmieri, Caramia, Scalise, Ferrante, Giovannini & Bernardi 
(1998) Subacute combined degeneration in a patient with partial epilepsy symptomatic 
of coeliac disease: Neurophysiologic evaluation. Bollettino - Lega Italiana contro 
l'Epilessia, 102 (103), 219-221 
Requested via interlibrary loans: English translation not available 
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APPENDICES FOR EMPIRICAL PAPER 
Appendix A – Questionnaire Pack 
 
 
Psycho-Social Factors   
in   
Coeliac Disease  
Adults with Coeliac Disease Questionnaire Pack  
Research Team: 
• Dr Ruth Howard - Clinical Psychologist  
• Dr Gary Law - Clinical Psychologist  
• Dr Jan Oyebode - Clinical Psychologist  
• Dr Jane Petty - Research Fellow   
 
School of Psychology, University of Birmingham, Edgbaston, Birmingham, B15 2TT.   
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The Illness Perception Questionnaire (IPQR)  
Your views about your Coeliac Disease (CD)  
Listed below are a number of symptoms that you may or may not have experienced since 
being diagnosed with CD. Please indicate by circling Yes or No, whether you have 
experienced any of these symptoms and if you have, whether you believe that these 
symptoms are related to your CD.   
        I have experienced this   This symptom is   
 symptom since my CD  caused by my CD  
Abdominal pain   Yes  No       Yes  No   
Sore throat    Yes  No  Yes  No   
Nausea    Yes  No  Yes  No   
Weight loss    Yes  No  Yes  No   
Fatigue    Yes  No  Yes  No   
Stiff joints    Yes  No  Yes  No   
Sore eyes    Yes  No  Yes  No   
Headaches    Yes  No  Yes  No   
Upset stomach/ diarrhoea    Yes  No  Yes  No   
Sleep difficulties    Yes  No  Yes  No   
Dizziness    Yes  No  Yes  No   
Loss of strength    Yes  No  Yes  No   
Bloating    Yes  No  Yes  No   
Excessive wind    Yes  No  Yes  No   
Breathlessness    Yes  No  Yes  No   
Constipation    Yes  No  Yes  No   
Heartburn/ indigestion    Yes  No  Yes  No   
Mouth ulcers    Yes  No  Yes  No   
Wheeziness    Yes  No  Yes  No   
Hair loss    Yes  No  Yes  No   
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We are interested in your own personal views of how you now see your Coeliac Disease 
(CD). Please indicate how much you agree or disagree with the following statements about 
your CD by ticking the correct box. 
(Disagree a lot: Disagree: Neither agree nor disagree: Agree: Agree a lot)  
My CD will last a short time.           
My CD is likely to be permanent rather than temporary.            
My CD will last for a long time.          
My CD will pass quickly.            
I expect to have CD for the rest of my life.            
My CD is a serious condition.            
My CD has major consequences on my life.            
My CD does not have much effect on my life.            
My CD strongly affects the way others see me.            
My CD has serious financial consequences.            
My CD causes difficulties for those who are close to me.            
There is a lot which I can do to control my symptoms.            
What I do can determine whether my CD gets better or worse.           
The course of my CD depends on me.            
Nothing I do will affect my CD.            
I have the power to influence my CD.            
My actions will have no effect on the outcome of my CD.            
My CD will improve in time.           
There is very little that can be done to improve my CD.    
My gluten-free diet will be effective in curing my CD.            
The negative effects of my CD can be prevented (avoided) by my diet.         
My gluten-free diet can control my CD.         
There is nothing that can help my CD.          
The symptoms of CD are puzzling to me.            
My CD is a mystery to me.            
I don’t understand my CD.            
My CD doesn’t make any sense to me.       
I have a clear picture or understanding of my CD.            
The symptoms of my CD change a great deal from day to day.        
My symptoms come and go in cycles.            
My CD is very unpredictable.            
I go through cycles in which my CD gets better and worse.            
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I get depressed when I think about my CD.            
When I think about my CD I get upset.        
My CD makes me feel angry.          
My CD does not worry me.           
Having CD makes me feel anxious.            
My CD makes me feel afraid.  
 
Following your Gluten Free Diet for Coeliac Disease 
Sometimes it’s hard to follow a gluten-free diet in certain situations. Some of these situations 
are listed in this questionnaire. We would like to know how confident you are that you would 
be able to regularly follow your gluten-free diet in these situations.  
Using the scale below, please indicate how confident you are in your ability to follow your 
gluten-free diet on a regular basis by writing a number between 0 and 10 next to each 
situation. If the statement does not apply to you please write 'N/A'.   
 
For example: ‘Going to the cinema with friends’  
When I go to the cinema with my friends they buy lots of foods that are not gluten free, like 
hotdogs and pick ‘n’ mix sweets. I feel like buying the same foods.  
In that situation I am not very confident that I would resist buying those foods so my 
confidence score = 2.  
If I always stick to my gluten-free diet when I go to the cinema with my friends, my 
confidence score = 10.  
       
Confidence Scale             
 0  1  2  3  4  5  6  7  8  9  10  
Not at all            Totally    
confident           confident 
          
Choose a number between 0 and 10 to show how confident you are that you could stick to 
your gluten-free diet...  
When I’m watching television at home    
When I’m feeling tired or bored    
When I’m alone at home    
When I’m feeling anxious, stressed or worried    
When I see friends eating non- gluten-free foods    
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When I am upset    
When eating out at my favourite restaurant    
When I’m on holiday and staying in a hotel    
When I’m feeling annoyed or angry    
When it is difficult to get hold of the foods I should eat for my gluten-free diet because the 
chemist cannot fill my prescription  
When I’m out and about and get very hungry    
When I’m feeling sad 
When I’m celebrating with others (e.g. at a birthday party)    
When I’m preparing non- gluten-free food for other people    
When eating out at a friend’s house    
When I’m offered non- gluten-free foods    
When non- gluten-free foods are available at home    
When it is difficult to get hold of the foods I should eat for my gluten-free diet because the 
supermarket does not have my usual items  
When I’m eating out at an unknown restaurant    
When I am ill    
When I’m on holiday and catering for myself (e.g. self-catering)    
At parties when non- gluten-free food is offered to me    
When I am in a hurry    
When I’m preparing my own meal    
When I’m faced with appealing foods that are not gluten-free in a supermarket, vending 
machine, or café  
When my life doesn’t go to plan    
When I’m feeling well (i.e. healthy, no symptoms)    
When I’m on holiday and eating in restaurants    
When I want more variety in my diet    
When I’m craving foods containing gluten    
When I’m on the way to or from work    
When I’m staying in hospital   
When I’m travelling (e.g. by aeroplane, train etc)    
When I’m not sure if something is gluten-free or not 
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The Coeliac Disease Questionnaire (CDQ)  
This questionnaire has been developed to find out how you have been feeling during the last 
two weeks. You will be asked about symptoms related to your Coeliac Disease, your general 
well-being and your mood. The questionnaire contains 28 questions. Each question offers 
seven possible answers ranked (1) to (7). Please read each question carefully and circle the 
answer that best describes how you felt during the past two weeks.  
(Very much so: Quite a bit: Sometimes: A little: Not at all) 
During the last two weeks...                
How many times was your life affected by a sudden urge to visit a bathroom for a bowel 
movement?   
How often did you feel physically exhausted or fatigued?          
How often have you felt frustrated, impatient or restless?           
How many times did you refuse or avoid an invitation for dinner with friends or relatives due 
to your Coeliac Disease?                 
How often have your bowel movements been loose?           
How often were you concerned that your children could inherit or may have inherited your 
Coeliac Disease?                 
How often have you been troubled by cramps in your abdomen?          
How much intellectual energy did you have?              
Did you encounter any difficulties with recreational activities or sports due to your CD?   
How often did you feel depressed or discouraged?             
How often did you suffer from bloating or flatulence?          
People with CD often have worries and fears related to their disease. How often did you 
worry about or were afraid of getting cancer as a result of your CD?       
How often were you affected by a feeling of incomplete bowel evacuation?        
How often have you felt relaxed and free of tension?            
How often did you feel isolated of excluded by others due to your CD?         
How often have you felt tearful or upset?                 
How often did you suffer from repeated belching?                
To what extent did your CD restrict your sexual activity?           
How satisfied, happy or pleased have you been with your personal life?         
How often did you suffer from nausea or retching?              
How often did you feel that important people such as members of your family or friends 
showed a lack of understanding for your CD?              
How often did you feel that colleagues or superiors showed a lack of understanding for your 
CD?   
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How often did you feel limited in your professional training or career by your CD?    
How often did you feel burdened by the expenses and time required obtaining gluten-free 
food?    
How often did you feel burdened by problems with meeting the costs of gluten-free food or 
other coeliac therapies?                 
How often did you experience lack of expertise regarding CD from your doctors?     
How often did you worry that your CD was diagnosed too late?          
How often did you suffer from fear of medical examinations in relation to your CD, e.g. 
blood test or endoscopy?    
 
The Brief COPE  
These questions deal with ways you've been coping with your Coeliac Disease and gluten-
free diet in the last month. There are many ways to try to deal with stressful situations.  
Obviously, different people deal with things in different ways, but I'm interested in how 
you've tried to deal with it.  Each item says something about a particular way of coping.  I 
want to know to what extent you've been doing what the item says.  How much or how 
frequently.  Don't answer on the basis of whether it seems to be working or not—just whether 
or not you've been doing it.    
(I haven’t done this at all: I’ve done this a little bit: I’ve done this a medium amount: I’ve 
done this a lot) 
I've been turning to work or other activities to take my mind off things.     
I've been concentrating my efforts on doing something about the situation I'm in.      
I've been saying to myself "this isn't real.".           
I've been using alcohol or other drugs to make myself feel better.           
I've been getting emotional support from others.           
I've been giving up trying to deal with it.           
I've been taking action to try to make the situation better.           
I've been refusing to believe that it has happened.           
I've been saying things to let my unpleasant feelings escape.           
I’ve been getting help and advice from other people.           
I've been using alcohol or other drugs to help me get through it.           
I've been trying to see it in a different light, to make it seem more positive.    
I’ve been criticizing myself.      
I've been trying to come up with a strategy about what to do.           
I've been getting comfort and understanding from someone.            
I've been giving up the attempt to cope.           
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I've been looking for something good in what is happening.           
I've been making jokes about it.      
I've been doing something to think about it less, such as going to movies, watching TV, 
reading, daydreaming, sleeping, or shopping.           
I've been accepting the reality of the fact that it has happened.           
I've been expressing my negative feelings.           
I've been trying to find comfort in my religion or spiritual beliefs.           
I’ve been trying to get advice or help from other people about what to do.        
I've been learning to live with it.       
I've been thinking hard about what steps to take.           
I’ve been blaming myself for things that happened.          
I've been trying to see it in a different light, to make it seem more positive.    
I've been praying or meditating.       
I've been making fun of the situation.   
 
DASS 21  
Please read each statement and circle a number 0, 1, 2 or 3 which indicates how much the 
statement applied to you over the past week. There are no right or wrong answers. Do not 
spend too much time on any statement.   
 
The rating scale is as follows:  
0 Did not apply to me at all  
1 Applied to me to some degree, or some of the time  
2 Applied to me to a considerable degree, or a good part of the time  
3 Applied to me very much, or most of the time  
I found it hard to wind down                                                                               
I was aware of dryness in my mouth                                                               
I couldn’t seem to experience any positive feeling at all                                
I experienced breathing difficulty (eg, excessively rapid breathing, breathlessness in the 
absence of physical exertion)  
I found it difficult to work up the initiative to do things                                    
I tended to over-react to situations                     
I experienced trembling (eg, in the hands)    
I felt that I was using a lot of nervous energy    
I was worried about situations in which I might panic and make a fool of myself   
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I felt that I had nothing to look forward to    
I found myself getting agitated    
I found it difficult to relax    
I felt down-hearted and blue    
I was intolerant of anything that kept me from getting on with what I was doing   
I felt I was close to panic    
I was unable to become enthusiastic about anything    
I felt I wasn’t worth much as a person    
I felt that I was rather touchy    
I was aware of the action of my heart in the absence of physical exertion (eg, sense of heart 
rate increase, heart missing a beat)   
I felt scared without any good reason     
I felt that life was meaningless    
 
Diagnosis of Coeliac Disease  
How were you diagnosed with Coeliac Disease?  
Through an intestinal biopsy and blood test            
Through an intestinal biopsy alone            
Through a blood test alone            
I diagnosed myself based on my symptoms and/or my reaction to dietary changes   
Other (please specify)  
 
Do you have any other long-term health conditions?   
Do you have any other food intolerances? (please select all that apply)  
Dairy (lactose)  
Fructose      
Alcohol  
Yeast        
Caffeine  
No other intolerance  
Other (please specify)  
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About Your Gluten-Free Diet  
In the last two weeks...    
How often have you knowingly eaten foods containing gluten while at home?   
How often have you knowingly eaten foods containing gluten when away from home?   
(Never: Once or twice: A few times: Daily: All the time)      
 
In general...   
How well do you stick to your gluten-free diet when you are at home?         
How well do you stick to your gluten-free diet when you are away from home?      
(Extremely well: Well: Quite well: Not very well: Not at all) 
       
How concerned are you about accidental gluten-ingestion? (Extremely concerned: Very 
concerned: Quite concerned: A little concerned: Not concerned at all)   
   
How harmful do you feel accidental gluten-exposure is to your health? (Extremely harmful: 
Very harmful: Quite harmful: A little harmful: Not at all harmful) 
        
How often do you see a dietician about your Coeliac Disease?  
Every 3 months or more frequently 
Every 6 months   
Every 12 months  
Every 2 years   
Every 3 years or less frequently   
I've never seen a dietician about my Coeliac Disease 
 
When did you last see a dietician about your Coeliac Disease?  
When was your last antibody blood test?  
What was the result of the test?  (Normal: Can’t remember: Abnormal: Haven’t had a blood 
test) 
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Where you given a score (number) for the test? If so, can you remember what it was?  
Food Quiz!  
 
We'd like to know a little bit about your knowledge of gluten-free foods. Please read the 
items below and choose 'Yes' if you think the item is gluten-free and 'No' if you think it is 
not. If you're not sure, or you feel there is insufficient information to be sure, please score the 
item as 'Not sure'.  
Modified starch        
Potato starch        
Monosodium glutamate        
Seasoning        
Flavouring        
Xanthum gum       
Modified wheat starch        
Edible starch        
Malt extract        
Colouring        
Hydrolysed vegetable protein (HVP)       
Cereal binder        
Textured Vegetable protein (TVP)        
Added fibre        
Gluten free wheat starch        
Yeast extract        
Powdered egg       
Vanilla essence        
Reduced gluten        
Rusk        
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About You  
You’re nearly there! The last few questions are about you.   
Are you male or female?   
What is your date of birth?  
When were you diagnosed with Coeliac Disease?  
Are you a member of Coeliac UK?  
 Yes             No 
If yes, how long have you been a member?  
What is your marital status?  
Single 
Cohabiting 
Married  
Separated 
Widowed 
Divorced 
 
What is your highest level of education?  
School, no qualifications 
School with qualifications 
University qualifications 
Postgraduate qualifications 
Vocational training/qualifications                 
 
What is or was your highest level of occupation?  
Professional 
Managerial or technical 
Non-manual skilled 
Manual skilled 
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Partly skilled 
Unskilled 
Home maker 
 
Which ethnic group do you belong to?  
White British 
White other 
Asian 
Black 
Other (please specify)  
Chinese 
Mixed – White and Asian 
Mixed – White and Black 
Other mixed background 
 
And Finally...  
I give my permission for the research team to contact me about this and future research 
projects. I understand that this does not obligate me to take part in any further research.  
    
Yes    No 
 
                      
Thank You!  
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Appendix B – Ethics approval letter 
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Appendix C - Illustrations of significant x~m pathways for DASS and CDQ 
respectively 
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Appendix D - Illustrations of significant xw~m pathways for DASS and CDQ 
respectively including amount of variance explained by each model 
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